Klinik für Psychiatrie und Psychotherapie: Erfasste Publikationen

[ Zeitschriften und Buchbeiträge ]

2022  2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998

 

2022

 

• Guo, N., Fuermaier, A. B. M., Koerts, J., Tucha, O., Scherbaum, N., & Muller, B. W. (2022). Networks of Neuropsychological Functions in the Clinical Evaluation of Adult ADHD. Assessment, 10731911221118673. doi: 10.1177/10731911221118673

 

• Schumacher F, Edwards MJ, Mühle C, Carpinteiro A, Wilson G, Wilker B,
  Soddemann M, Keitsch S, Scherbaum N, Müller BW, Lang UE, Linnemann C, Kleuser B, Müller CP,
  Kornhuber J, Gulbins E, Ceramide levels in blood plasma correlate with major depressive disorder
  severity and its neutralization abrogates depressive behavior in mice, Journal of Biological Chemistry
  (2022), doi: https://doi.org/10.1016/j.jbc.2022.102185

 

• ​It Takes Time: Vigilance and Sustained Attention Assessment in Adults with ADHD https://doi.org/10.3390/ijerph19095216 Fuermaier, A.B.M.; Tucha, L.; Guo, N.; Mette, C.; Müller, B.W.; Scherbaum, N.; Tucha, O. Int. J. Environ. Res. Public Health 2022, 19, 5216. https://doi.org/10.3390/ijerph19095216 

 

2021

 

• Cortical thickness across the cingulate gyrus in schizophrenia and its association to illness duration and memory performance. Thielen, J.-W., Müller, B. W., Chang, D.-I., Krug, A., Mehl, S., Rapp, A., Walter, H., Winterer, G., Vogeley, K., Klingberg, S., Wagner, M., & Kircher, T. (2021). European Archives of Psychiatry and Clinical Neuroscience, in press.

 

• Shared genetic risk between eating disorder- and substance-use-related phenotypes: Evidence from genome-wide association studies
  Addict Biol. 2021 Jan;26(1):e12880. Epub 2020 Feb 16.
  Munn-Chernoff MA, Johnson EC, Chou YL, Coleman JRI, Thornton LM, Walters RK, Yilmaz Z, Baker JH, Hübel C, Gordon S, Medland SE, Watson HJ, Gaspar HA, Bryois J, Hinney A, Leppä VM, Mattheisen M, Ripke S, Yao S, Giusti-Rodríguez P, Hanscombe KB, Adan RAH, Alfredsson L, Ando T, Andreassen OA, Berrettini WH, Boehm I, Boni C, Boraska Perica V, Buehren K, Burghardt R, Cassina M, Cichon S, Clementi M, Cone RD, Courtet P, Crow S, Crowley JJ, Danner UN, Davis OSP, de Zwaan M, Dedoussis G, Degortes D, DeSocio JE, Dick DM, Dikeos D, Dina C, Dmitrzak-Weglarz M, Docampo E, Duncan LE, Egberts K, Ehrlich S, Escaramís G, Esko T, Estivill X, Farmer A, Favaro A, Fernández-Aranda F, Fichter MM, Fischer K, Föcker M, Foretova L, Forstner AJ, Forzan M, Franklin CS, Gallinger S, Giegling I, Giuranna J, Gonidakis F, Gorwood P, Gratacos Mayora M, Guillaume S, Guo Y, Hakonarson H, Hatzikotoulas K, Hauser J, Hebebrand J, Helder SG, Herms S, Herpertz-Dahlmann B, Herzog W, Huckins LM, Hudson JI, Imgart H, Inoko H, Janout V, Jiménez-Murcia S, Julià A, Kalsi G, Kaminská D, Karhunen L, Karwautz A, Kas MJH, Kennedy JL, Keski-Rahkonen A, Kiezebrink K, Kim YR, Klump KL, Knudsen GPS, La Via MC, Le Hellard S, Levitan RD, Li D, Lilenfeld L, Lin BD, Lissowska J, Luykx J, Magistretti PJ, Maj M, Mannik K, Marsal S, Marshall CR, Mattingsdal M, McDevitt S, McGuffin P, Metspalu A, Meulenbelt I, Micali N, Mitchell K, Monteleone AM, Monteleone P, Nacmias B, Navratilova M, Ntalla I, O'Toole JK, Ophoff RA, Padyukov L, Palotie A, Pantel J, Papezova H, Pinto D, Rabionet R, Raevuori A, Ramoz N, Reichborn-Kjennerud T, Ricca V, Ripatti S, Ritschel F, Roberts M, Rotondo A, Rujescu D, Rybakowski F, Santonastaso P, Scherag A, Scherer SW, Schmidt U, Schork NJ, Schosser A, Seitz J, Slachtova L, Slagboom PE, Slof-Op't Landt MCT, Slopien A, Sorbi S, Świątkowska B, Szatkiewicz JP, Tachmazidou I, Tenconi E, Tortorella A, Tozzi F, Treasure J, Tsitsika A, Tyszkiewicz-Nwafor M, Tziouvas K, van Elburg AA, van Furth EF, Wagner G, Walton E, Widen E, Zeggini E, Zerwas S, Zipfel S, Bergen AW, Boden JM, Brandt H, Crawford S, Halmi KA, Horwood LJ, Johnson C, Kaplan AS, Kaye WH, Mitchell J, Olsen CM, Pearson JF, Pedersen NL, Strober M, Werge T, Whiteman DC, Woodside DB, Grove J, Henders AK, Larsen JT, Parker R, Petersen LV, Jordan J, Kennedy MA, Birgegård A, Lichtenstein P, Norring C, Landén M, Mortensen PB, Polimanti R, McClintick JN, Adkins AE, Aliev F, Bacanu SA, Batzler A, Bertelsen S, Biernacka JM, Bigdeli TB, Chen LS, Clarke TK, Degenhardt F, Docherty AR, Edwards AC, Foo JC, Fox L, Frank J, Hack LM, Hartmann AM, Hartz SM, Heilmann-Heimbach S, Hodgkinson C, Hoffmann P, Hottenga JJ, Konte B, Lahti J, Lahti-Pulkkinen M, Lai D, Ligthart L, Loukola A, Maher BS, Mbarek H, McIntosh AM, McQueen MB, Meyers JL, Milaneschi Y, Palviainen T, Peterson RE, Ryu E, Saccone NL, Salvatore JE, Sanchez-Roige S, Schwandt M, Sherva R, Streit F, Strohmaier J, Thomas N, Wang JC, Webb BT, Wedow R, Wetherill L, Wills AG, Zhou H, Boardman JD, Chen D, Choi DS, Copeland WE, Culverhouse RC, Dahmen N, Degenhardt L, Domingue BW, Frye MA, Gäebel W, Hayward C, Ising M, Keyes M, Kiefer F, Koller G, Kramer J, Kuperman S, Lucae S, Lynskey MT, Maier W, Mann K, Männistö S, Müller-Myhsok B, Murray AD, Nurnberger JI, Preuss U, Räikkönen K, Reynolds MD, Ridinger M, Scherbaum N, Schuckit MA, Soyka M, Treutlein J, Witt SH, Wodarz N, Zill P, Adkins DE, Boomsma DI, Bierut LJ, Brown SA, Bucholz KK, Costello EJ, de Wit H, Diazgranados N, Eriksson JG, Farrer LA, Foroud TM, Gillespie NA, Goate AM, Goldman D, Grucza RA, Hancock DB, Harris KM, Hesselbrock V, Hewitt JK, Hopfer CJ, Iacono WG, Johnson EO, Karpyak VM, Kendler KS, Kranzler HR, Krauter K, Lind PA, McGue M, MacKillop J, Madden PAF, Maes HH, Magnusson PKE, Nelson EC, Nöthen MM, Palmer AA, Penninx BWJH, Porjesz B, Rice JP, Rietschel M, Riley BP, Rose RJ, Shen PH, Silberg J, Stallings MC, Tarter RE, Vanyukov MM, Vrieze S, Wall TL, Whitfield JB, Zhao H, Neale BM, Wade TD, Heath AC, Montgomery GW, Martin NG, Sullivan PF, Kaprio J, Breen G, Gelernter J, Edenberg HJ, Bulik CM, Agrawal A.

 

• The role of self- and informant-reports on symptoms and impairments in the clinical evaluation of adult ADHD Guo, N., Fuermaier, A. B. M., Koerts, J., Mueller, B. W., Mette, C., Tucha, L., Scherbaum, N., & Tucha, O. (2021). . Sustainability 2021 Vol. 13 Pages 4565. doi: 10.3390/su13084564

 

 

• Abwägung von Nutzen und Schädlichkeit von berauschenden und schmerzlindernden Substanzen aus der Perspektive von deutschen Suchtmedizinern
  Fortschr Neurol Psychiatr. 2021.
  Bonnet U, Specka M, Soyka M, Alberti T, Bender S, Hilger J, Hillemacher T, Kuhlmann T, Kuhn J, Lüdecke C, Reimer J, Schneider U, Schroeder W, Stuppe M, Wiesbeck G, Wodarz N, Scherbaum N.

 

• Evaluation of the German biographic screening interview for fetal alcohol spectrum disorder (BSI-FASD)
  Sci Rep. 2021 Mar 4;11(1):5233. PMID: 33664281; PMCID: PMC7933170.
  Widder M, Mierzwa L, Schwerg L, Schecke H, Kornhuber J, Bouna-Pyrrou P, Bumb JM, Richter-Schmidinger T, Lenz B.
   

 

• Substitution treatment for opioid dependence with slow-release oral morphine: Retention rate, health status, and substance use after switching to morphine
  Journal of Substance Abuse Treatment, Volume 127, 2021,108350.
  Lehmann K, Kuhn S, Baschirotto C, Jacobsen B, Walcher S, Görne H, Backmund M, Scherbaum N, Reimer J, Verthein U.

 

• Are Persons Treated with Antidepressants and/or Antipsychotics Possibly Better Protected against Severe COVID 19?
  Pharmacopsychiatry. 2021 Mar 17. Epub ahead of print.
  Bonnet U, Juckel G, Scherbaum N, Schaefer M, Kis B, Cohen S, Kuhn J.

 

• The e-psychonaut drugs’ psychopharmacology
  Current Opinion in Pharmacology 2021, 57:165-174
  Schifano F, Chiappini S, Corkery JM, Scherbaum N, Guirguis A

 

• Substanzkonsum, Abhängigkeitserkrankung und Strafvollzug
  Forum Strafvollzug, 01/2021: 7-12; https://forum-strafvollzug.de/
  Deimel D

 

• Comment on "Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update"
  Drugs (2021) 81:611–614; https://doi.org/10.1007/s40265-021-01494-1 Bonnet U, McAnally H, Scherbaum N

 

• The Role of Self- and Informant-Reports on Symptoms and Impairments in the Clinical Evaluation of Adult ADHD
  Sustainability 2021, 13, 4564. https://doi.org/10.3390/su13084564
  Guo, N.; Fuermaier, A.B.M.; Koerts, J.; Mueller, B.W.; Mette, C.; Tucha, L.; Scherbaum, N.; Tucha, O.

 

• Availability of Illegal Drugs During the COVID-19 Pandemic in Western Germany.
  Front. Psychiatry 2021, 12:648273. doi: 10.3389/fpsyt.2021.648273
  Scherbaum N, Bonnet U, Hafermann H, Schifano F, Bender S, Grigoleit T, Kuhn J, Nyhuis P, Preuss UW, Reymann G, Schneider U, Shibata J and Specka M

 

• Substances detected in used syringes of injecting drug users across 7 cities in Europe in 2017 and 2018: The European Syringe Collection and Analysis Project Enterprise (ESCAPE).
  Int J Drug Policy. 2021 Jan 22:103130. doi: 10.1016/j.drugpo.2021.103130. Epub ahead of print.
  Brunt TM, Lefrançois E, Gunnar T, Arponen A, Seyler T, Goudriaan AE, McAuley A, McKeown DA, Detrez V, Csorba J, Deimel D, Auwärter V, Kempf J, Karolak S, Nefau T.

 

• Sexual dysfunction in patients with adult attention deficit hyperactivity disorder: A pilot study
  The Canadian Journal of Human Sexuality 2021 30:1, 106-113. https://doi.org/10.3138/cjhs.2020-0036
  Abdel-Hamid M, Basilowski M, Schönfeld B, Bartels C, Anderson-Schmidt H, Hessmann P, Kownatka M, Dehghan-Vratonjic S, Krieger S, Scherbaum N, Wiltfang W, Kis B, and Signerski-Krieger J

 

• Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as potential biomarker for Alzeimer’s disease
  Alzheimer's Research & Therapy (2021) 13:94. https://doi.org/10.1186/s13195-021-00828-1
  Aichholzer F, Klafki HW, Ogorek I, Vogelsang J, Wiltfang J, Scherbaum N, Weggen S, Wirths O.

 

• Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries.
  Front. Psychiatry 2021, 12:676224. doi: 10.3389/fpsyt.2021.676224
  Fonseca F, Lenahan W, Dart RC, Papaseit E, Dargan PI, Wood DM, Guareschi M, Maremmani I, Auriacombe M, Farré M, Scherbaum N and Torrens M

 

• Corrigendum: Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment.
  Front. Psychiatry 2021, 12:681542. doi: 10.3389/fpsyt.2021.681542
  Specka M, Kuhlmann T, Sawazki J, Bonnet U, Steinert R, Cybulska-Rycicki M, Eich H, Zeiske B, Niedersteberg A, Schaaf L and Scherbaum N

​

 

• Opioid painkiller dependence in a sample of elderly medical inpatients
  Psychogeriatrics 2021; 21: 265-271. doi:10.1111/psyg.12658
  Chiappini S, Schifano F, Martinotti G, Strasser JC, Bonnet U, Scherbaum N.

 

• Psychiatry training in 42 European countries: A comparative analysis.
  Eur Neuropsychopharmacol. 2021 May;46:68-82. doi: 10.1016/j.euroneuro.2021.02.003
  Baessler F, Zafar A, Gargot T, da Costa MP, Biskup EM, De Picker L, Koelkebeck K, Riese F, Ryland H, Kazakova O, Birkle S, Kanellopoulos T, Grassl R, Braicu A, Schultz JH, Casanova Dias M.
   
• FASTER and SCOTT&EVA trainings for adults with high-functioning autism spectrum disorder (ASD): study protocol for a randomized controlled trial.
  Trials. 2021 Apr 8;22(1):261. doi: 10.1186/s13063-021-05205-9
  Tebartz van Elst L, Fangmeier T, Schaller UM, Hennig O, Kieser M, Koelkebeck K, Kuepper C, Roessner V, Wildgruber D, Dziobek I.

 

• Trail Making Test Normative Data for the German Older Population.
  Arch Clin Neuropsychol. 2021 Apr 30:acab027. doi: 10.1093/arclin/acab027.
  Specka M, Weimar C, Stang A, Jöckel KH, Scherbaum N, Hoffmann SS, Kowall B, Jokisch M.

 

• Attentional processes during emotional face perception in social anxiety disorder: A systematic review and meta-analysis of eye-tracking findings.
  Prog Neuropsychopharmacol Biol Psychiatry. 2021 May 15;111:110353. doi: 10.1016/j.pnpbp.2021.110353. Epub ahead of print.
  Günther V, Kropidlowski A, Schmidt FM, Koelkebeck K, Kersting A, Suslow T. 

 

• Patient with Asperger´s syndrome and lesion of the right amygdala: emotional face recognition deficits.
  Frontiers in Psychology, Emotion Science 2021, in press
  Koelkebeck K, Bauer J, Suslow T, Pedersen A, Ohrmann P.

 

• Klotho KL-VS haplotype does not improve cognition in a population-based sample of adults age 55 to 87 years.
  Scientific Reports 2021, Sci Rep 11, 13852 (2021). https://doi.org/10.1038/s41598-021-93211-x
  Müller, B. W., Hinney, A., Scherbaum, N., Weimar, C., Kleinschnitz, C., Peters, T., Hochfeld, L., Pechlivanis, S., Stang, A., Jokisch, M., & Kowall, B. 

 

• Heroin-assisted treatment of heroin-addicted patients normalizes regulatory T cells but does not restore CD4⁺ T cell proliferation.
  Addict Biol. 2021 Jul;26(4):e12998. doi: 10.1111/adb.12998.
  Hansen W, Luppus S, Barthel R, Chang DI, Broemstrup J, Zwarg T, Shibata J, Westendorf AM, Buer J, Scherbaum N.

 

• COVID-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis. 
  Brain Sciences. 2021; 11(7):907. https://doi.org/10.3390/brainsci11070907 Arillotta D, Guirguis A, Corkery JM, Scherbaum N, Schifano F.

 

• Efficacy of Temporally Intensified Exposure for Anxiety Disorders: A Multi-Center Randomized Clinical Trial, angenommen in Depression and Anxiety
  accepted
  Pittig A, Heinig I, Goerig S, Thiel F, Hummel K, Scholl L, Deckert J, Pauli P, Domschke K, Lueken U,  Fydrich T, Fehm L, Plag J, Ströhle A, Kircher K, Straube B, Rief W, Koelkebeck K, Arolt V, Dannlowski U, Margraf J, Totzeck C, Schneider S, Neudeck P, Craske MG, Hollandt M, Richter J, Hamm A, Wittchen HU.

 

• Family members’ perspectives of child protection services, a metasynthesis of the literature
  Children and Youth Services Review 2021; 128, https://doi.org/10.1016/j.childyouth.2021.106094.
  Bekaert S, Paavilainen E, Schecke H, Baldacchino A, Jouet E, Zabłocka – Żytka L, Bachi B, Bartoli F, Carrà G, Cioni RM, Crocamo C, Appleton JV

 

• The Psychonauts’ Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity.
  Pharmaceuticals. 2021; 14(8):720. https://doi.org/10.3390/ph14080720
  Catalani V, Botha M, Corkery JM, Guirguis A, Vento A, Scherbaum N, Schifano F.

 

• Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.
  Nat Commun. 2021 Jun 7;12(1):3417. doi: 10.1038/s41467-021-22491-8.

          de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen IE, Pedersen NL, Stringa N, Zettergren A, et. al. […]              Scherbaum N, […] Lambert JC, van der Lee SJ, Ruiz A.

 

2020

• Brain Changes Induced by Electroconvulsive Therapy Are Broadly Distributed.
  Biol Psychiatry. 2020;87(5): 451-461 (Impact(2017)=11.982, Typ=Journal Article)
  Ousdal OT, Argyelan M, Narr KL, Abbott C, Wade B, Vandenbulcke M, Urretavizcaya M, Tendolkar I, Takamiya A, Stek ML, Soriano-Mas C, Redlich R, Paulson OB, Oudega ML, Opel N, Nordanskog P, Kishimoto T, Kampe R, Jorgensen A, Hanson LG, Hamilton JP, Espinoza R, Emsell L, van Eijndhoven P, Dols A, Dannlowski U, Cardoner N, Bouckaert F, Anand A, Bartsch H, Kessler U, Oedegaard KJ, Dale AM, Oltedal L, GEMRIC , Erchinger VJ, Haavik J, Evjenth Sørhaug OJ, Jørgensen MB, Bolwig TG, Magnusson P, Cano M, Pujol J, Menchón JM, Petrides G, Sienaert P
   
• Patient-Centered Placement Matching of Alcohol-Dependent Patients Based on a Standardized Intake Assessment: Primary Outcomes of an Exploratory Randomized Controlled Trial.
  Eur Addict Res. 2020;26(3): 109-121 (Impact(2017)=2.653, Typ=Journal Article; Randomized Controlled Trial)
  Buchholz A, Dams J, Rosahl A, Hempleman J, König HH, Konnopka A, Kraus L, Kriston L, Piontek D, Reimer J, Röhrig J, Scherbaum N, Silkens A, Berner M
   
• Impact of Buprenorphine Dosage on the Occurrence of Relapses in Patients with Opioid Dependence.
  Eur Addict Res. 2020;26(2): 77-84 (Impact(2017)=2.653, Typ=Journal Article)
  Reimer J, Vogelmann T, Trümper D, Scherbaum N
   
• Psychosocial burden and body mass index are associated with dermatology-related quality of life in psoriasis patients.
  Eur J Dermatol. 2020;30(2): 140-147 (Impact(2017)=1.944, Typ=Journal Article)
  Sondermann W, Schreiber A, Körber A, Fiege O, Scherbaum N, Benson S, Schedlowski M
   
• Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment.
  Front Psychiatry. 2020;11: 569 (Impact(2017)=2.857, Typ=Journal Article)
  Specka M, Kuhlmann T, Sawazki J, Bonnet U, Steinert R, Cybulska-Rycicki M, Eich H, Zeiske B, Niedersteberg A, Schaaf L, Scherbaum N
   
• [Scientific Rationale for the Directive on Opioid Substitution Treatment of the German Medical Association: A Summary].
  Gesundheitswesen. 2020; (Impact(2017)=0.993, Typ=Journal Article; English Abstract)
  Kunstmann W, Specka M, Wodarz N, Scherbaum N
   
• High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing.
  Harm Reduct J. 2020;17(1): 7 (Impact: liegt nicht vor, Typ=Journal Article; Research Support, Non-U.S. Gov't)
  Enkelmann J, Gassowski M, Nielsen S, Wenz B, Roß S, Marcus U, Bremer V, Zimmermann R, DRUCK Study group , Bock CT, Bannert N, Santos-Hövener C, Scherbaum N, Klee J, Hecht A, Schaeffer D
   
• Psychosocial emergency care in times of COVID-19: the Essen University Hospital concept for corona-infected patients, their relatives, and medical staff.
  Int Arch Occup Environ Health. 2020; (Impact(2017)=2.148, Typ=Letter)
  Rentrop V, Schneider JS, Bäuerle A, Junne F, Dörrie N, Skoda EM, Schedlowski M, Mallmann B, Benecke AV, Kohler H, Gerigk M, Teigelack P, Emler T, Scherbaum N, Gradl-Dietsch G, Scheer K, Teufel M
   
• Microdosing psychedelics: Motivations, subjective effects and harm reduction.
  Int J Drug Policy. 2020;75: 102600 (Impact(2017)=4.244, Typ=Journal Article)
  Lea T, Amada N, Jungaberle H, Schecke H, Klein M
   
• Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study.
  Open Forum Infect Dis. 2020;7(8): ofaa317 (Impact(2017)=3.24, Typ=Journal Article)
  Schulte B, Schmidt CS, Manthey J, Strada L, Christensen S, Cimander K, Görne H, Khaykin P, Scherbaum N, Walcher S, Mauss S, Schäfer I, Verthein U, Rehm J, Reimer J
   
• Rate of opioid use disorder in adults who received prescription opioid pain therapy-A secondary data analysis.
  PLoS ONE. 2020;15(7): e0236268 (Impact(2017)=2.766, Typ=Journal Article)
  Just JM, Scherbaum N, Specka M, Puth MT, Weckbecker K
   
• Very Low Frequency of Drug Therapy of Alcohol Dependence in Germany - Analysis of Data of A Statutory Health Insurance.
  Pharmacopsychiatry. 2020;53(1): 37-39 (Impact(2017)=2.064, Typ=Letter; Journal Article)
  Scherbaum N, Holzbach R, Stammen G, Kirchof U, Bonnet U
   
• Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.
  Psychopharmacology (Berl). 2020;237(5): 1521-1532 (Impact(2017)=3.222, Typ=Journal Article)
  Lea T, Amada N, Jungaberle H, Schecke H, Scherbaum N, Klein M
   
• Effectiveness of an Adjunctive Psychotherapeutic Intervention Developed for Enhancing the Placebo Effect of Antidepressants Used within an Inpatient-Treatment Program of Major Depression: A Pragmatic Parallel-Group, Randomized Controlled Trial.
  Psychother Psychosom. 2020;89(4): 258-260 (Impact(2017)=13.122, Typ=Letter)
  Claus BB, Scherbaum N, Bonnet U
   
• Predictors of attendance in outpatient group treatment for women with posttraumatic stress disorder and substance use disorder.
  Psychother Res. 2020;: 1-12 (Impact(2017)=2.953, Typ=Journal Article)
  Grundmann J, Lotzin A, Sehner S, Verthein U, Hiller P, Hiersemann R, Lincoln TM, Hillemacher T, Schneider B, Driessen M, Scherbaum N, Dotten AC, Schäfer I
   
• Long-term opioid therapy of non-cancer pain : Prevalence and predictors of hospitalization in the event of possible misuse.
  Schmerz. 2020;34(Suppl 1): 8-15 (Impact(2017)=1.215, Typ=Journal Article)
  Häuser W, Schubert T, Scherbaum N, Tölle T
   
• Implementation of opioid maintenance treatment in prisons in North Rhine-Westphalia, Germany - a top down approach.
  Subst/ Abus Treatment Prev Pol. 2020;15(1): 21 (Impact(2017)=2.214, Typ=Journal Article)
  Böhmer K, Schecke H, Render I, Scherbaum N
   
• Cannabis hyperemesis syndrome: A specific cannabis-related disorder?
  Neurogastroenterol Motil. 2020 Jan;32(1):e13723. doi: 10.1111/nmo.13723
  Bonnet U.

 

• Theory of Mind, emotion recognition, delusions and the quality of the therapeutic relationship in patients with psychosis – a secondary analysis of a randomized controlled therapy trial
  BMC Psychiatry. 2020 Feb 10;20(1):59.  doi: 10.1186/s12888-020-2482-z.
  Mehl S, Hesse K, Schmidt AC, Landsberg MW, Soll D, Bechdolf A, Herrlich J, Kircher T, Klingberg S, Mueller B, Wiedemann G, Wittorf A, Woelwer W & Wagner M.

 

• Topiramate Decelerates Bicarbonate-Driven Acid-Elimination of Human Neocortical Neurons: Strategic Significance for its Antiepileptic, Antimigraine and Neuroprotective Properties.
  CNS Neurol Disord Drug Targets. 2020;19(4):264-275. doi: 10.2174/1871527319666200604173208.
  Bonnet U, Wiemann M.

 

• Chemsex and Mental Health of Men Who Have Sex With Men in Germany.
  Front. Psychiatry 2020, 11:542301. doi: 10.3389/fpsyt.2020.542301
  Bohn A, Sander D, Köhler T, Hees N, Oswald F, Scherbaum N, Deimel D and Schecke H

 

• Editorial: New Trends of Substance Abuse: Looking for New Psychotropic Effects of Chem Sex Drugs, Cognitive Enhancers, and New Psychoactive Substances.
  Front. Psychiatry 2020, 11:612192. doi: 10.3389/fpsyt.2020.612192
  Pichini S, Di Trana A, Torrens M, Scherbaum N and Zaami S
• Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?
  Front Psychiatry. 2020 Dec 3;11:598150. doi: 10.3389/fpsyt.2020.598150. eCollection 2020.
  Claus BB, Specka M, McAnally H, Scherbaum N, Schifano F, Bonnet U.

 

• Amygdalar nuclei and hippocampal subfields on MRI: test-retest reliability of automated volumetry across different MRI sites and vendors.
  Neuroimage. 2020 May 13:116932. doi: 10.1016/j.neuroimage.2020.116932. [Epub ahead of print]
  Quattrini G, Pievani M, Jovicich J, Aiello M, Bargalló N, Barkhof F, Bartres-Faz D, Beltramello A, Pizzini FB, Blin O, Bordet R, Caulo M, Constantinides M, Didic M, Drevelegas A, Ferretti A, Fiedler U, Floridi P, Gros-Dagnac H, Hensch T, Hoffmann KT, Kuijer JP, Lopes R, Marra C, Müller BW, Nobili F, Parnetti L, Payoux P, Picco A, Ranjeva JP, Roccatagliata L, Rossini PM, Salvatore M, Schonknecht P, Schott BH, Sein J, Soricelli A, Tarducci R, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Frisoni GB, Marizzoni M; PharmaCog Consortium.

 

• Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth.

          Pain Ther. 2020 Dec;9(2):441-452. doi: 10.1007/s40122-020-00189-x. Epub 2020 Jul 31.
          McAnally H, Bonnet U, Kaye AD.

 

• High lifetime, but low current, prevalence of new psychotropic substances (NPS) use in German drug detoxification treatment young inpatients.

         Prog Neuropsychopharmacol Biol Psychiatry. 2020 Oct 19:110144. doi: 10.1016/j.pnpbp.2020.110144.  
         Scherbaum N, Seiffert F, Schifano F, Specka M, Bonnet U, Bender S.

 

• Ranking the Harm of Psychoactive Drugs Including Prescription Analgesics to Users and Others-A Perspective of German Addiction Medicine Experts.
  Front Psychiatry. 2020 Oct 26;11:592199. doi: 10.3389/fpsyt.2020.592199. eCollection 2020
  Bonnet U, Specka M, Soyka M, Alberti T, Bender S, Grigoleit T, Hermle L, Hilger J, Hillemacher T, Kuhlmann T, Kuhn J, Luckhaus C, Lüdecke C, Reimer J, Schneider U, Schroeder W, Stuppe M, Wiesbeck GA, Wodarz N, McAnally H, Scherbaum N.

 

• Structural changes induced by electroconvulsive therapy are associated with clinical outcome.
  Brain Stimul. 2020 May-Jun;13(3):696-704. doi: 10.1016/j.brs.2020.02.020. Epub 2020 Feb 21
  Mulders PCR, Llera A, Beckmann CF, Vandenbulcke M, Stek M, Sienaert P, Redlich R, Petrides G, Oudega ML, Oltedal L, Oedegaard KJ, Narr KL, Magnusson PO, Kessler U, Jorgensen A, Espinoza R, Enneking V, Emsell L, Dols A, Dannlowski U, Bolwig TG, Bartsch H, Argyelan M, Anand A, Abbott CC, van Eijndhoven PFP, Tendolkar I.

 

• Longitudinal effects of rTMS on neuroplasticity in chronic treatment-resistant depression.
  Eur Arch Psychiatry Clin Neurosci. 2021 Feb;271(1):39-47. doi: 10.1007/s00406-020-01135-w. Epub 2020 May 9.
  Dalhuisen I, Ackermans E, Martens L, Mulders P, Bartholomeus J, de Bruijn A, Spijker J, van Eijndhoven P, Tendolkar I.

 

• A large-scale genome-wide association study meta-analysis of cannabis use disorder.
  Lancet Psychiatry. 2020 Dec;7(12):1032-1045. doi: 10.1016/S2215-0366(20)30339-4. Epub 2020 Oct 20
  Johnson EC, Demontis D, Thorgeirsson TE, Walters RK, Polimanti R, Hatoum AS, Sanchez-Roige S, Paul SE, Wendt FR, Clarke TK, Lai D, Reginsson GW, Zhou H, He J, Baranger DAA, Gudbjartsson DF, Wedow R, Adkins DE, Adkins AE, Alexander J, Bacanu SA, Bigdeli TB, Boden J, Brown SA, Bucholz KK, Bybjerg-Grauholm J, Corley RP, Degenhardt L, Dick DM, Domingue BW, Fox L, Goate AM, Gordon SD, Hack LM, Hancock DB, Hartz SM, Hickie IB, Hougaard DM, Krauter K, Lind PA, McClintick JN, McQueen MB, Meyers JL, Montgomery GW, Mors O, Mortensen PB, Nordentoft M, Pearson JF, Peterson RE, Reynolds MD, Rice JP, Runarsdottir V, Saccone NL, Sherva R, Silberg JL, Tarter RE, Tyrfingsson T, Wall TL, Webb BT, Werge T, Wetherill L, Wright MJ, Zellers S, Adams MJ, Bierut LJ, Boardman JD, Copeland WE, Farrer LA, Foroud TM, Gillespie NA, Grucza RA, Harris KM, Heath AC, Hesselbrock V, Hewitt JK, Hopfer CJ, Horwood J, Iacono WG, Johnson EO, Kendler KS, Kennedy MA, Kranzler HR, Madden PAF, Maes HH, Maher BS, Martin NG, McGue M, McIntosh AM, Medland SE, Nelson EC, Porjesz B, Riley BP, Stallings MC, Vanyukov MM, Vrieze S; Psychiatric Genomics Consortium Substance Use Disorders Workgroup, Davis LK, Bogdan R, Gelernter J, Edenberg HJ, Stefansson K, Børglum AD, Agrawal A.

 

• Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients - Results of the COMPAS Study.
  Pharmacopsychiatry. 2020 Nov;53(6):263-271. doi: 10.1055/a-1207-9851. Epub 2020 Oct 5
  Kis B, Lücke C, Abdel-Hamid M, Heßmann P, Graf E, Berger M, Matthies S, Borel P, Sobanski E, Alm B, Rösler M, Retz W, Jacob C, Colla M, Huss M, Jans T, van Elst LT, Müller HHO, Philipsen A.

 

• Psychological burden of psoriatic patients in a German university hospital dermatology department.
  J Dermatol. 2020 Dec 22. doi: 10.1111/1346-8138.15721. Epub ahead of print. Sondermann W, Fiege O, Körber A, Scherbaum N.

 

• Heroin-assisted treatment of heroin-addicted patients normalizes regulatory T cells but does not restore CD4⁺ T cell proliferation.
  Addict Biol. 2020 Dec 17:e12998. doi: 10.1111/adb.12998.
  Hansen W, Luppus S, Barthel R, Chang DI, Broemstrup J, Zwarg T, Shibata J, Westendorf AM, Buer J, Scherbaum N

 

2019

2018

2017

2016

2015

 

2014

 Zepf FD, Sánchez CL, Biskup CS, Kötting WF, Bubenzer S, Helmbold K, Eisert A, Gaber TJ, Landgraf M, Dahmen B, Poustka F, Wöckel L, Stadler C, Grabemann M, Mette C, Heinrich V, Uekermann J, Abdel-Hamid M, Kis B, Zimmermann M, Wiltfang J, Kuhn CM. Acute tryptophan depletion - converging evidence for decreasing central nervous serotonin synthesis in rodents and humans. Acta Psychiatr Scand. 2014;129(2): 157-9

Hinney A, Albayrak O, Antel J, Volckmar AL, Sims R, Chapman J, Harold D, Gerrish A, Heid IM, Winkler TW, Scherag A, Wiltfang J, Williams J, Hebebrand J, GERAD Consortium , IGAP Consortium , GIANT Consortium. Genetic variation at the CELF1 (CUGBP, elav-like family member 1 gene) locus is genome-wide associated with Alzheimer's disease and obesity. Am J Med Genet B Neuropsychiatr Genet. 2014;165B(4): 283-93

Philipsen A, Graf E, Jans T, Matthies S, Borel P, Colla M, Gentschow L, Langner D, Jacob C, Groß-Lesch S, Sobanski E, Alm B, Schumacher-Stien M, Roesler M, Retz W, Retz-Junginger P, Kis B, Abdel-Hamid M, Heinrich V, Huss M, Kornmann C, Bürger A, van Elst LT, Berger M. A randomized controlled multicenter trial on the multimodal treatment of adult attention-deficit hyperactivity disorder: enrollment and characteristics of the study sample. Atten Defic Hyperact Disord. 2014;6(1): 35-47

Krug A, Cabanis M, Pyka M, Pauly K, Walter H, Landsberg M, Shah NJ, Winterer G, Wölwer W, Musso F, Müller BW, Wiedemann G, Herrlich J, Schnell K, Vogeley K, Schilbach L, Langohr K, Rapp A, Klingberg S, Kircher T. Investigation of decision-making under uncertainty in healthy subjects: A multi-centric fMRI study. Behav Brain Res. 2014;261: 89-96

Specka M, Heilmann M, Lieb B, Scherbaum N. Use of disulfiram for alcohol relapse prevention in patients in opioid maintenance treatment. Clin Neuropharmacol. 2014;37(6): 161-5

Bonnet U, Specka M, Stratmann U, Ochwadt R, Scherbaum N. Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum. Drug Alcohol Depend. 2014;143: 189-97

Galluzzi S, Marizzoni M, Babiloni C, Bartres-Faz D, Blin O, Bordet R, Bosch B, De Anna F, Didic M, Farotti L, Forloni G, Jovicich J, Marra C, Marzano N, Molinuevo JL, Nobili F, Pariente J, Parnetti L, Payoux P, Picco A, Quaranta D, Ranjeva JP, Roccatagliata L, Rossini PM, Salvadori N, Schonknecht P, Soricelli A, Tsolaki M, Vecchio F, Visser PJ, Wiltfang J, Frisoni GB, PharmaCog Consortium. Cross-sectional clinical, neuropsychological, neuroimaging, and neurophysiological characterization of mild cognitive impairment patients in WP5 PharmaCog/E-ADNI study. Eur J Neurol. 2014;21 1: 106-106

Lennertz L, Wagner M, Grabe HJ, Franke PE, Guttenthaler V, Rampacher F, Schulze-Rauschenbach S, Vogeley A, Benninghoff J, Ruhrmann S, Pukrop R, Klosterkötter J, Falkai P, Maier W, Mössner R. 5-HT3 receptor influences the washing phenotype and visual organization in obsessive-compulsive disorder supporting 5-HT3 receptor antagonists as novel treatment option. Eur Neuropsychopharmacol. 2014;24(1): 86-94

Reissner V, Mühe B, Wellenbrock S, Kuhnigk O, Kis B, Dietrich H, Hebebrand J. DSM-IV-TR Axes-I and II mental disorders in a representative and referred sample of unemployed youths - results from a psychiatric liaison service in a job centre. Eur Psychiatry. 2014;29(4): 239-45

Scherbaum N, Schifano F, Siemann H. New psychotropic drugs - "legal highs". Fortschr Neurol Psychiatr. 2014;82(9): 532-43; quiz 543-4

Apelt SM, Scherbaum N, Soyka M. Induction and switch to buprenorphine-naloxone in opioid dependence treatment: Predictive value of the first four weeks. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS. 2014;16(3): 87-97

Kuhn E, Potthoff A, Dirks H, Borgmann R, Wolter M, Esser S, Scherbaum N, Brockmeyer NH. Viral Load Strategy: Essentials, Popularity and Impact on Sexual Risk Behavior and Serocommunication of MSM in Specialized Outpatient Care. J Dtsch Dermatol Ges. 2014;12(10): 980-981

Thoens C, Berger C, Trippler M, Siemann H, Lutterbeck M, Broering R, Schlaak J, Heinemann FM, Heinold A, Nattermann J, Scherbaum N, Alter G, Timm J. KIR2DL3(+)NKG2A(-) natural killer cells are associated with protection from productive hepatitis C virus infection in people who inject drugs. J Hepatol. 2014;61(3): 475-81

Galluzzi S, Marizzoni M, Babiloni C, Bartres-Faz D, Blin O, Bordet R, Bosch B, De Anna F, Didic M, Farotti L, Forloni G, Jovicich J, Marra C, Marzano N, Molinuevo JL, Nobili F, Pariente J, Parnetti L, Payoux P, Picco A, Quaranta D, Ranjeva JP, Roccatagliata L, Rossini PM, Salvadori N, Schonknecht P, Soricelli A, Tsolaki M, Vecchio F, Visser PJ, Wiltfang J, Frisoni GB, PharmaCog Consortium. Cross-sectional clinical, neuropsychological, neuroimaging, and neurophysiological characterization of mild cognitive impairment patients in WP5 PharmaCog/E-ADNI study. J Neurol. 2014;261 1: S76-S77

Poschmann G, Seyfarth K, Besong Agbo D, Klafki HW, Rozman J, Wurst W, Wiltfang J, Meyer HE, Klingenspor M, Stühler K. High-fat diet induced isoform changes of the Parkinson's disease protein DJ-1. J Proteome Res. 2014;13(5): 2339-51

Seo BK, Sartory G, Kis B, Scherbaum N, Muller BW. Intensity Dependence of Auditory Evoked Potentials (IDAP) in Adult Attention Deficit/Hyperactivity (ADHD) Disorder. J Psychophysiol. 2014;28(2): 63-72

Liu G, Yao L, Liu J, Jiang Y, Ma G, Genetic and Environmental Risk for Alzheimer's disease (GERAD1) Consortium , Chen Z, Zhao B, Li K, Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Chapman J, Russo G, Hamshere M, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Morgan K, Brown K, Passmore P, Craig D, McGuinness B, Todd S, Johnston J, Holmes C, Mann D, Smith A, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Heun R, Kölsch H, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate A, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Holmans P, O'Donovan M, Owen MJ, Williams J. Cardiovascular disease contributes to Alzheimer's disease: evidence from large-scale genome-wide association studies. Neurobiol Aging. 2014;35(4): 786-92

Deuschle M, Schilling C, Leweke FM, Enning F, Pollmächer T, Esselmann H, Wiltfang J, Frölich L, Heuser I. Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau. Neurosci Lett. 2014;561: 41-5

Kärgel C, Sartory G, Kariofillis D, Wiltfang J, Müller BW. Mismatch negativity latency and cognitive function in schizophrenia. PLoS ONE. 2014;9(4): e84536

Konnopka A, Stuhldreher N, Klingberg S, Wittorf A, Bechdolf A, Müller BW, Sartory G, Wagner M, Wiedemann G, Wölwer W, Heinrich S, König HH. Determinants of direct cost in schizophrenia patients with persistent positive symptoms. Psychiatr Prax. 2014;41(4): 215-20

Grabemann M, Mette C, Zimmermann M, Wiltfang J, Kis B. Serum albumin correlates with affective prosody in adult males with attention-deficit hyperactivity disorder. Psychiatry Res. 2014;217(3): 198-201

Radke S, Güths F, André JA, Müller BW, de Bruijn ER. In action or inaction? Social approach-avoidance tendencies in major depression. Psychiatry Res. 2014;219(3): 513-7

Turner D, Driemeyer W, Nieder TO, Scherbaum N, Briken P. 'How Much Sex do Medical Studies Need?' - A Survey of the Knowledge and Interest in Sexual Medicine of Medical Students. Psychother Psychosom Med Psychol. 2014;64(12): 452-457

Scherbaum N, Specka M. Comorbid Mental Disorders in Opiate Dependents. SUCHTTHERAPIE. 2014;15(1): 22-28

Mehl S, Landsberg MW, Schmidt AC, Cabanis M, Bechdolf A, Herrlich J, Loos-Jankowiak S, Kircher T, Kiszkenow S, Klingberg S, Kommescher M, Moritz S, Müller BW, Sartory G, Wiedemann G, Wittorf A, Wölwer W, Wagner M. Why do bad things happen to me? Attributional style, depressed mood, and persecutory delusions in patients with schizophrenia. Schizophr Bull. 2014;40(6): 1338-46

Krug A, Cabanis M, Pyka M, Pauly K, Kellermann T, Walter H, Wagner M, Landsberg M, Shah NJ, Winterer G, Wölwer W, Brinkmeyer J, Müller BW, Kärgel C, Wiedemann G, Herrlich J, Vogeley K, Schilbach L, Rapp A, Klingberg S, Kircher T. Attenuated prefrontal activation during decision-making under uncertainty in schizophrenia: A multi-center fMRI study. Schizophr Res. 2014;152(1): 176-83

Schuller U, Fiedler U, Scherbaum N. Psychotherapeutic Clinical Day Treatment of Oncology Patients in the Geronto-psychiatric Setting. Strahlenther Onkol. 2014;190 1: 128-128

Schieber K, Lindner M, Sowa JP, Gerken G, Scherbaum N, Kahraman A, Canbay A, Erim Y. THE INFLUENCE OF THE SETTING ON ALCOHOL SELF-REPORTS: A COMPARISON OF THE SETTING OF LIVER TRANSPLANTATION AND REHABILITATION THERAPY. Transpl Int. 2014;27 3: 35-35

Kariofillis, D., Sartory, G., Kärgel, C., Müller, B.W. (2014). The effect of cognitive training on evoked potentials in schizophrenia. Schiz.Res.Cog., 1 (4), 180-186. doi: 10.1016/j.scog. 2014.07.001.

Radke, S., Güths, F., André, J. A., Müller, B. W., & De Bruin, E. R. A. (2014). In action or inaction? Social approach-avoidance tendencies in major depression. Psychiatry Res. 219(3), 513-517. doi: 10.1016/j.psychres.2014.07.011

Mehl, S., Landsberg, M.W., Schmidt, A.-C., Cabanis, M., Bechdolf, A., Herrlich, J., Loos-Jankowiak, S., Kircher, T., Kiszkenow, S., Klingberg, S., Kommescher, M., Moritz, S., Sartory, G., Müller, B.W., Wiedemann, G., Wittorf, A., Wölwer, W., Wagner, M. (2014). Why do bad things happen to me? Attributional style, depressed mood, and persecutory delusions in patients with schizophrenia. Schizophrenia Bulletin, 40(6), 1338-1346. doi: 10.1093/schbul/sbu040

Kärgel, C., Sartory, G., Kariofillis, D., Wiltfang, J., & Müller, B. W. (2014). Mismatch negativity latency and cognitive function in schizophrenia. PLoS ONE, 9(4), e84536. doi: 10.1371/journal.pone.0084536

Schiffer, B., Pawliczek, C., Müller, B.W., Forsting, M., Gizewski, E.R., Leygraf, N., Hodgins, S. (2014). Neural mechanisms underlying cognitive control of men with lifelong antisocial behavior. Psychiatry Research: Neuroimaging, 222 (1-29), 43-51.

Seo, B.-K., Sartory, G., Kis, B., Scherbaum, N., Müller, B.W. (2014). Intensity dependence of auditory evoked potentials (IDAP) in adult attention deficit/hyperactivity (ADHD) disorder. Journal of Psychophysiology, 28 (2), 63-72.

Krug, A., Cabanis, M., Pyka, M., Pauly, K., Walter, H., Landsberg, M., Shah, N. J., Winterer, G., Wölwer, W., Musso, F., Müller, B. W., Wiedemann, G., Herrlich, J., Schnell, K., Vogeley, K., Schilbach, L., Langohr, K., Rapp, A., Klingberg, S., & Kircher, T. (2014). Investigation of decision-making under uncertainty in healthy subjects: A multi-centric fMRI study. Behavioural Brain Research, 261, 89-96.

Krug, A., Cabanis, M., Pyka, M., Pauly, K., Kellermann, T., Walter, H., Wagner, M., Landsberg, M., Shah, N. J., Winterer, G., Wölwer, W., Brinkmeyer, J., Müller, B. W., Kärgel, C., Wiedemann, G., Herrlich, J., Vogeley, K., Schilbach, L., Rapp, A., Klingberg, S., & Kircher, T. (2014). Attenuated prefrontal activation during decision-making under uncertainty in schizophrenia: A multi-centre fMRI study. Schizophrenia Research, 152(1), 176-183.

Konnopka, A., Stuhldreher, N., Klingberg, S., Wittorf, A., Bechdolf, A., Müller, B. W., Sartory, G., Wagner, M., Wiedemann, G., Wölwer, W., Heinrich, S., & König, H. H. (2014). Determinanten direkter Kosten bei persistierender Positivsymptomatik psychotischer Erkrankungen [Determinants of Direct Cost in Schizophrenia Patients with Persistent Positive Symptoms.]. Psychiatrische Praxis, 41 (4), 215-220.

Radke, S., Güths, F., André, J. A., Müller, B. W., & De Bruin, E. R. A. (in press). In action or inaction? Social approach-avoidance tendencies in major depression. Psychiatry Res.

Mehl, S., Landsberg, M.W., Schmidt, A.-C., Cabanis, M., Bechdolf, A., Herrlich, J., Loos-Jankowiak, S., Kircher, T., Kiszkenow, S., Klingberg, S., Kommescher, M., Moritz, S., Sartory, G., Müller, B.W., Wiedemann, G., Wittorf, A., Wölwer, W., Wagner, M. (2014). Why do bad things happen to me? Attributional style, depressed mood, and persecutory delusions in patients with schizophrenia. Schizophrenia Bulletin, in press. doi: 10.1093/schbul/sbu040

Kärgel, C., Sartory, G., Kariofillis, D., Wiltfang, J., & Müller, B. W. (2014). Mismatch negativity latency and cognitive function in schizophrenia. PLoS ONE, 9(4), e84536. doi: 10.1371/journal.pone.0084536

Schiffer, B., Pawliczek, C., Müller, B.W., Forsting, M., Gizewski, E.R., Leygraf, N., Hodgins, S. (2014). Neural mechanisms underlying cognitive control of men with lifelong antisocial behavior. Psychiatry Research: Neuroimaging, 222 (1-29), 43-51.

Seo, B.-K., Sartory, G., Kis, B., Scherbaum, N., Müller, B.W. (2014). Intensity dependence of auditory evoked potentials (IDAP) in adult attention deficit/hyperactivity (ADHD) disorder. Journal of Psychophysiology, 28 (2), 63-72.

Krug, A., Cabanis, M., Pyka, M., Pauly, K., Walter, H., Landsberg, M., Shah, N. J., Winterer, G., Wölwer, W., Musso, F., Müller, B. W., Wiedemann, G., Herrlich, J., Schnell, K., Vogeley, K., Schilbach, L., Langohr, K., Rapp, A., Klingberg, S., & Kircher, T. (2014). Investigation of decision-making under uncertainty in healthy subjects: A multi-centric fMRI study. Behavioural Brain Research, 261, 89-96.

Krug, A., Cabanis, M., Pyka, M., Pauly, K., Kellermann, T., Walter, H., Wagner, M., Landsberg, M., Shah, N. J., Winterer, G., Wölwer, W., Brinkmeyer, J., Müller, B. W., Kärgel, C., Wiedemann, G., Herrlich, J., Vogeley, K., Schilbach, L., Rapp, A., Klingberg, S., & Kircher, T. (2014). Attenuated prefrontal activation during decision-making under uncertainty in schizophrenia: A multi-centre fMRI study. Schizophrenia Research, 152(1), 176-183.

Konnopka, A., Stuhldreher, N., Klingberg, S., Wittorf, A., Bechdolf, A., Müller, B. W., Sartory, G., Wagner, M., Wiedemann, G., Wölwer, W., Heinrich, S., & König, H. H. (2014). Determinanten direkter Kosten bei persistierender Positivsymptomatik psychotischer Erkrankungen [Determinants of Direct Cost in Schizophrenia Patients with Persistent Positive Symptoms.]. Psychiatrische Praxis, 41 (4), 215-220.  

2013

Grabemann M, Mette C, Zimmermann M, Heinrich V, Uekermann J, Wiltfang J, Abdel-Hamid M, Zepf FD, Kis B. No clear effects of acute tryptophan depletion on processing affective prosody in male adults with ADHD. Acta Psychiatr Scand. 2013;128(2): 142-8

Mette C, Zimmermann M, Grabemann M, Abdel-Hamid M, Uekermann J, Biskup CS, Wiltfang J, Zepf FD, Kis B. The impact of acute tryptophan depletion on attentional performance in adult patients with ADHD. Acta Psychiatr Scand. 2013;128(2): 124-32

Gizewski ER, Müller BW, Scherbaum N, Lieb B, Forsting M, Wiltfang J, Leygraf N, Schiffer B. The impact of alcohol dependence on social brain function. Addict Biol. 2013;18(1): 109-20

Agbo DBesong, Klafki H, Poschmann G, Seyfarth K, Genius J, Janssen C, Stuehler K, Wurst W, Meyer HE, Klingenspor M, Wiltfang J. Development of a capillary isoelectric focusing immunoassay to measure DJ-1 isoforms in biological samples. Anal Biochem. 2013;443(2): 197-204

Haußmann U, Jahn O, Linning P, Janßen C, Liepold T, Portelius E, Zetterberg H, Bauer C, Schuchhardt J, Knölker HJ, Klafki H, Wiltfang J. Analysis of amino-terminal variants of amyloid-ß peptides by capillary isoelectric focusing immunoassay. Anal Chem. 2013;85(17): 8142-9

Specka M, Böning A, Kluwig J, Schifano F, Banger M, Lange W, Lax H, Marrziniak B, Schüngel C, Scherbaum N. Can reinforcement-based interventions to reduce drug use successfully be adapted to routine opioid maintenance treatment? Ann Ist Super Sanita. 2013;49(4): 358-64

Reimer J, Schmidt CS, Schulte B, Gansefort D, Golz J, Gerken G, Scherbaum N, Verthein U, Backmund M. Psychoeducation Improves Hepatitis C Virus Treatment During Opioid Substitution Therapy: A Controlled, Prospective Multicenter Trial. Clin Infect Dis. 2013;57 2: S97-S104

Kraemer M, Herold M, Uekermann J, Kis B, Wiltfang J, Daum I, Dziobek I, Berlit P, Diehl RR, Abdel-Hamid M. Theory of mind and empathy in patients at an early stage of relapsing remitting multiple sclerosis. Clin Neurol Neurosurg. 2013;115(7): 1016-22

Cabanis M, Pyka M, Mehl S, Müller BW, Loos-Jankowiak S, Winterer G, Wölwer W, Musso F, Klingberg S, Rapp AM, Langohr K, Wiedemann G, Herrlich J, Walter H, Wagner M, Schnell K, Vogeley K, Kockler H, Shah NJ, Stöcker T, Thienel R, Pauly K, Krug A, Kircher T. The precuneus and the insula in self-attributional processes. Cogn Affect Behav Neurosci. 2013;13(2): 330-45

Kueper M, Zoeller M, Liebeskind S, Wiltfang J, Benninghoff J. PET Imaging in a Case of the Semantic Variant of Primary Progressive Aphasia. Fortschr Neurol Psychiatr. 2013;81(7): E14-E16

Scherbaum N, Lieb B. Opiate dependency. Fortschr Neurol Psychiatr. 2013;81(6): 346-57; quiz 358

Steil C, Meiler B, Wiesten I, Wiltfang J, Kis B. TANDEM (TAsk force oN long Duration unemployment of Elderly People and Mental health) implementation of a cross-institutional pilot project for elderly long-term unemployed persons - presentation of the project procedure and the utilisation. Gesundheitswesen. 2013;75(8-9): e113-8

Alho H, Auriacombe M, Fischer G, Maremmani I, Scherbaum N, Torrens M. Can outcomes monitoring of opioid maintenance treatment be improved in Europe? A statement by some European experts with interests in opioid maintenance treatment and its safety. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS. 2013;15(1): 63-64

Chapman J, Rees E, Harold D, Ivanov D, Gerrish A, Sims R, Hollingworth P, Stretton A, GERAD1 Consortium , Holmans P, Owen MJ, O'Donovan MC, Williams J, Kirov G, Harold D, Sims R, Gerrish A, Chapman J, Moskvina V, Abraham R, Hollingworth P, Hamshere M, Pahwa JS, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Williams K, Thomas S, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown K, Passmore P, Craig D, McGuinness B, Johnston JA, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Guerreiro R, Singleton A, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Heun R, Kölsch H, Schürmann B, Ramirez A, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate A, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Nöthen MM, Holmans P, O'Donovan M, Owen MJ, Williams J. A genome-wide study shows a limited contribution of rare copy number variants to Alzheimer's disease risk. Hum Mol Genet. 2013;22(4): 816-24

Lee SH, Harold D, Nyholt DR, ANZGene Consortium , International Endogene Consortium , Genetic and Environmental Risk for Alzheimer's disease Consortium , Goddard ME, Zondervan KT, Williams J, Montgomery GW, Wray NR, Visscher PM, Harold D, Sims R, Gerrish A, Chapman J, Moskvina V, Abraham R, Hollingworth P, Hamshere M, Pahwa JS, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown K, Passmore P, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Heun R, Kölsch H, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate A, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Nöthen MM, Holmans P, O'Donovan M, Owen MJ, Williams J, Scott RJ, Lechner-Scott J, Moscato P, Booth DR, Stewart GJ, Heard RN, Mason D, Griffiths L, Broadley S, Brown MA, Slee M, Foote SJ, Stankovich J, Taylor BV, Wiley J, Bahlo M, Perreau V, Field J, Butzkueven H, Kilpatrick TJ, Rubio J, Marriott M, Carroll WM, Kermode AG, Anderson CA, Gordon SD, Guo Q, Henders AK, Lambert A, Lee SH, Kraft P, Kennedy SH, Macgregor S, Martin NG, Missmer SA, Montgomery GW, Morris AP, Nyholt DR, Painter JN, Roseman F, Treloar SA, Visscher PM, Wallace L, Zondervan KT. Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. Hum Mol Genet. 2013;22(4): 832-41

Corazza O, Assi S, Simonato P, Corkery J, Bersani FS, Demetrovics Z, Stair J, Fergus S, Pezzolesi C, Pasinetti M, Deluca P, Drummond C, Davey Z, Blaszko U, Moskalewicz J, Mervo B, Furia LD, Farre M, Flesland L, Pisarska A, Shapiro H, Siemann H, Skutle A, Sferrazza E, Torrens M, Sambola F, van der Kreeft P, Scherbaum N, Schifano F. Promoting innovation and excellence to face the rapid diffusion of Novel Psychoactive Substances in the EU: the outcomes of the ReDNet project. Hum Psychopharmacol. 2013;28(4): 317-23

Zahn D, Petrak F, Uhl I, Juckel G, Neubauer H, Hägele AK, Wiltfang J, Herpertz S. New pathways of increased cardiovascular risk in depression: A pilot study on the association of high-sensitivity C-reactive protein with pro-atherosclerotic markers in patients with depression. J Affect Disord. 2013;146(3): 420-5

Morgen K, Frölich L, Tost H, Plichta MM, Kölsch H, Rakebrandt F, Rienhoff O, Jessen F, Peters O, Jahn H, Luckhaus C, Hüll M, Gertz HJ, Schröder J, Hampel H, Teipel SJ, Pantel J, Heuser I, Wiltfang J, Rüther E, Kornhuber J, Maier W, Meyer-Lindenberg A. APOE-dependent phenotypes in subjects with mild cognitive impairment converting to Alzheimer's disease. J Alzheimers Dis. 2013;37(2): 389-401

Christiansen H, Hirsch O, Philipsen A, Oades RD, Matthies S, Hebebrand J, Ueckermann J, Abdel-Hamid M, Kraemer M, Wiltfang J, Graf E, Colla M, Sobanski E, Alm B, Rösler M, Jacob C, Jans T, Huss M, Schimmelmann BG, Kis B. German validation of the conners adult ADHD rating scale-self-report: confirmation of factor structure in a large sample of participants with ADHD. J Atten Disord. 2013;17(8): 690-8

Seo BK, Sartory G, Kis B, Scherbaum N, Müller BW. Attenuated Readiness Potential in the Absence of Executive Dysfunction in Adults With ADHD. J Atten Disord. 2013; DOI: 10.1177/1087054713508602

Kraemer M, Herold M, Uekermann J, Kis B, Daum I, Wiltfang J, Berlit P, Diehl RR, Abdel-Hamid M. Perception of affective prosody in patients at an early stage of relapsing-remitting multiple sclerosis. J Neuropsychol. 2013;7(1): 91-106

Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013;12(3): 233-43

Plate A, Benninghoff J, Jansen GH, Wlasich E, Eigenbrod S, Drzezga A, Jansen NL, Kretzschmar HA, Bötzel K, Rujescu D, Danek A. Atypical parkinsonism due to a D202N Gerstmann-Sträussler-Scheinker prion protein mutation: first in vivo diagnosed case. Mov Disord. 2013;28(2): 241-4

Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J, Alzheimer Genetic Analysis Group , Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Lupton MK, Ryten M, Brown K, Lowe J, Ridge PG, Hammer MB, Wakutani Y, Hazrati L, Proitsi P, Newhouse S, Lohmann E, Erginel-Unaltuna N, Medway C, Hanagasi H, Troakes C, Gurvit H, Bilgic B, Al-Sarraj S, Benitez B, Cooper B, Carrell D, Emre M, Zou F, Ma L, Murray M, Dickson D, Younkin S, Petersen RC, Corcoran CD, Cai Y, Oliveira C, Ribeiro MH, Santana I, Tschanz JT, Gibbs J, Norton MC, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Munger RG, Mann DM, Pickering-Brown S, Lovestone S, Beck J, Mead S, Collinge J, Parsons L, Pocock J, Morris JC, Revesz T, Lashley T, Fox NC, Rossor MN, Grenier-Boley B, Bellenguez C, Moskvina V, Sims R, Harold D, Williams J, Lambert JC, Amouyel P, Graff-Radford N, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J, Gerrish A, Chapman J, Abraham R, Hollingworth P, Hamshere M, Pahwa JS, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Williams K, Thomas S, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Passmore P, Craig D, McGuinness B, Johnston JA, Todd S, Holmes C, Smith A, Love S, Kehoe PG, Maier W, Jessen F, Heun R, Kölsch H, Schürmann B, Ramirez A, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Nowotny P, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Nöthen MM, Holmans P, O'Donovan M, Owen MJ, Zelenika D, Epelbaum J, Dartigues JF, Tzourio C, Berr C, Boland A, Campion D, Alpérovitch A, Lathrop M, Smith C, Trabzuni D, Walker R, Weale M. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2): 117-27

Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, ODonovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimers disease (vol 41, pg 1088, 2009). Nat Genet. 2013;45(6): 712-712

Jovicich J, Marizzoni M, Sala-Llonch R, Bosch B, Bartrés-Faz D, Arnold J, Benninghoff J, Wiltfang J, Roccatagliata L, Nobili F, Hensch T, Tränkner A, Schönknecht P, Leroy M, Lopes R, Bordet R, Chanoine V, Ranjeva JP, Didic M, Gros-Dagnac H, Payoux P, Zoccatelli G, Alessandrini F, Beltramello A, Bargalló N, Blin O, Frisoni GB, PharmaCog Consortium. Brain morphometry reproducibility in multi-center 3T MRI studies: a comparison of cross-sectional and longitudinal segmentations. Neuroimage. 2013;83: 472-84

Bauer J, Pedersen A, Scherbaum N, Bening J, Patschke J, Kugel H, Heindel W, Arolt V, Ohrmann P. Craving in alcohol-dependent patients after detoxification is related to glutamatergic dysfunction in the nucleus accumbens and the anterior cingulate cortex. Neuropsychopharmacology. 2013;38(8): 1401-8

Easton AlannaC, Lucchesi Walter, Lourdusamy Anbarasu, Lenz Bernd, Solati Jalal, Golub Yulia, Lewczuk Piotr, Fernandes Cathy, Desrivieres Sylvane, Dawirs RalphR, Moll GuntherH, Kornhuber Johannes, Frank Josef, Hoffmann Per, Soyka Michael, Kiefer Falk, Schumann Gunter, Giese KPeter, Mueller ChristianP, GESGA Consortium. aCaMKII Autophosphorylation Controls the Establishment of Alcohol Drinking Behavior (vol 38, pg 1636, 2013) Neuropsychopharmacology. 2013;38(13): 2735-2735

Easton AC, Lucchesi W, Lourdusamy A, Lenz B, Solati J, Golub Y, Lewczuk P, Fernandes C, Desrivieres S, Dawirs RR, Moll GH, Kornhuber J, Frank J, Hoffmann P, Soyka M, Kiefer F, GESGA Consortium , Schumann G, Peter Giese K, Müller CP, Treutlein J, Cichon S, Ridinger M, Mattheisen P, Herms S, Wodarz N, Zill P, Maier W, Mössner R, Gaebel W, Dahmen N, Scherbaum N, Schmäl C, Steffens M, Lucae S, Ising M, Müller-Myhsok B, Nöthen MM, Mann K, Rietschel M. aCaMKII autophosphorylation controls the establishment of alcohol drinking behavior. Neuropsychopharmacology. 2013;38(9): 1636-47

Genius J, Geiger J, Dölzer AL, Benninghoff J, Giegling I, Hartmann AM, Möller HJ, Rujescu D. Glutamatergic dysbalance and oxidative stress in in vivo and in vitro models of psychosis based on chronic NMDA receptor antagonism. PLoS ONE. 2013;8(7): e59395

Schiffer B, Pawliczek C, Müller BW, Gizewski ER, Walter H. Why don't men understand women? Altered neural networks for reading the language of male and female eyes. PLoS ONE. 2013;8(4): e60278

Zou F, Belbin O, Carrasquillo MM, Culley OJ, Hunter TA, Ma L, Bisceglio GD, Allen M, Dickson DW, Graff-Radford NR, Petersen RC, Genetic and Environmental Risk for Alzheimer's disease (GERAD1) Consortium , Morgan K, Younkin SG, Harold D, Sims R, Gerrish A, Chapman J, Moskvina V, Abraham R, Hollingworth P, Hamshere M, Pahwa JS, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Williams K, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown K, Passmore P, Craig D, McGuinness B, Johnston JA, Todd S, Holmes C, Mann D, Smith A, Love S, Kehoe PG, Hardy J, Guerreiro R, Singleton A, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Heun R, Schürmann B, Ramirez A, Herold C, Lacour A, Drichel D, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate A, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Nöthen MM, Holmans P, O'Donovan M, Owen MJ, Williams J. Linking protective GAB2 variants, increased cortical GAB2 expression and decreased Alzheimer's disease pathology. PLoS ONE. 2013;8(5): e64802

Apelt SM, Scherbaum N, Gölz J, Backmund M, Soyka M. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care. Pharmacopsychiatry. 2013;46(3): 94-107

Benninghoff J, Grunze H, Schindler C, Genius J, Schloesser RJ, van der Ven A, Dehning S, Wiltfang J, Möller HJ, Rujescu D. Ziprasidone - Not Haloperidol - Induces more de-novo Neurogenesis of Adult Neural Stem Cells Derived from Murine Hippocampus. Pharmacopsychiatry. 2013;46(1): 10-5

Gröttrup B, Esselmann H, May C, Schrötter A, Woitalla D, Heinsen H, Marcus K, Wiltfang J, Meyer HE, Grinberg LT, Park YM. Challenges in modern biomarker discovery--17th HUPO BPP workshop: May 24-25, 2012, Sao Paulo, Brazil. Proteomics. 2013;13(2): 210-6

Schroetter Andreas, El Magraoui Fouzi, Groettrup Bernd, Wiltfang Jens, Heinsen Helmut, Marcus Katrin, Meyer HelmutE, Grinberg LeaT, Park YoungMok. Early Diagnosis of Neurodegenerative Diseases - The Long Awaited Holy Grail and Bottleneck of Modern Brain Research-19th HUPO BPP Workshop May 22-24, 2013, Dortmund, Germany. Proteomics. 2013;13(20): 2938-2941

Radke S, Schäfer IC, Müller BW, de Bruijn ER. Do different fairness contexts and facial emotions motivate 'irrational' social decision-making in major depression? An exploratory patient study. Psychiatry Res. 2013;210(2): 438-43

Wittorf A, Jakobi-Malterre UE, Beulen S, Bechdolf A, Müller BW, Sartory G, Wagner M, Wiedemann G, Wölwer W, Herrlich J, Klingberg S. Associations between therapy skills and patient experiences of change processes in cognitive behavioral therapy for psychosis. Psychiatry Res. 2013;210(3): 702-9

Schifano F, Corazza O, Marchi A, Di Melchiorre G, Sferrazza E, Enea A, Davey Z, Blaszko U, Deluca P, Psychonaut web mapping e rednet research projects , Deluca P, Davey Z, Corazza O, Di Furia L, Farré M, Flesland L, Mannonen M, Majava A, Pagani S, Peltoniemi T, Pasinetti M, Pezzolesi C, Scherbaum N, Siemann H, Skutle A, Torrens M, Van Der Kreeft P, Schifano F, Corazza O, Davey Z, Demetrovics Z, Enea A, di Melchiorre G, Di Furia L, Flesland L, Scherbaum N, Siemann H, Torrens M, Shapiro H, Sferrazza E, van der Kreeft P, Schifano F. Analysis of online reports on the potential misuse of benzidamine. Riv Psichiatr. 2013;48(3): 182-6

Backmund M, Isernhagen K, Preuss UW, Ulmer A, Ehrenreich H, Kiefer F, Krampe H, Havemann-Reinecke U, Reimer J, Scherbaum N. Disulfiram - an important Therapeutic Option for Alcohol Addiction will disappear. SUCHTTHERAPIE. 2013;14(3): 140-U77

Schiffer B, Leygraf N, Müller BW, Scherbaum N, Forsting M, Wiltfang J, Gizewski ER, Hodgins S. Structural brain alterations associated with schizophrenia preceded by conduct disorder: a common and distinct subtype of schizophrenia? Schizophr Bull. 2013;39(5): 1115-28

Radbruch L, Glaeske G, Grond S, Münchberg F, Scherbaum N, Storz E, Tholen K, Zagermann-Muncke P, Zieglgänsberger W, Hoffmann-Menzel H, Greve H, Cremer-Schaeffer P. Topical review on the abuse and misuse potential of tramadol and tilidine in Germany. Subst Abus. 2013;34(3): 313-20

Benninghoff J, Rauh W, Brantl V, Schloesser RJ, Moessner R, Möller HJ, Rujescu D. Cholinergic impact on neuroplasticity drives muscarinic M1 receptor mediated differentiation into neurons. World J Biol Psychiatry. 2013;14(3): 241-6

Krug, A., Cabanis, M., Pyka, M., Pauly, K., Walter, H., Landsberg, M., Shah, N. J., Winterer, G., Wölwer, W., Musso, F., Müller, B. W., Wiedemann, G., Herrlich, J., Schnell, K., Vogeley, K., Schilbach, L., Langohr, K., Rapp, A., Klingberg, S., & Kircher, T. (2014). Investigation of decision-making under uncertainty in healthy subjects: A multi-centric fMRI study. Behavioural Brain Research, in press.

Seo, B.-K., Sartory, G., Kis, B., Scherbaum, N., Müller, B.W. (2014). Intensity dependence of auditory evoked potentials (IDAP) in adult attention deficit/hyperactivity (ADHD) disorder. Journal of Psychophysiology, in press

Krug, A., Cabanis, M., Pyka, M., Pauly, K., Kellermann, T., Walter, H., Wagner, M., Landsberg, M., Shah, N. J., Winterer, G., Wölwer, W., Brinkmeyer, J., Müller, B. W., Kärgel, C., Wiedemann, G., Herrlich, J., Vogeley, K., Schilbach, L., Rapp, A., Klingberg, S., & Kircher, T. (2013). Attenuated prefrontal activation during decision-making under uncertainty in schizophrenia: A multi-centre fMRI study. Schizophrenia Research, in press.

Seo, B-K, Sartory, G., Kis, B., Scherbaum, N., Müller, B.W. (2013). Attenuated readiness potential in the absence of executive dysfunction in adults with attention deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders, in press.

Konnopka, A., Stuhldreher, N., Klingberg, S., Wittorf, A., Bechdolf, A., Müller, B. W., Sartory, G., Wagner, M., Wiedemann, G., Wölwer, W., Heinrich, S., & König, H. H. (2013). Determinanten direkter Kosten bei persistierender Positivsymptomatik psychotischer Erkrankungen. Psychiatrische Praxis, in press.

Wittorf, A., Jakobi-Malterre, U. E., Beulen, S., Bechdolf, A., Müller, B. W., Sartory, G., Wagner, M., Wiedemann, G., Wölwer, W., Herrlich, J., Klingberg, S. (2013). Associations between therapy skills and patient experiences of change processes in cognitive behavioral therapy for psychosis. Psychiatry Research, in press.

Radke, S., Schäfer, I.C., Müller, B.W. & De Bruijn, E.R.A. (2013). Do different fairness contexts and facial emotions motivate 'irrational' social decision-making in major depression? An exploratory patient study. Psychiatry Research, in press.

Schiffer B, Pawliczek C, Müller BW, Gizewski E, Walter H. (2013). Why don't men understand women: Altered neural networks for reading the language of male and female eyes. PLOSone, 8:e60278.

Gizewski, E.R., Müller, B.W., Scherbaum, N., Lieb, B., Forsting, M., Wiltfang, J., Leygraf, N., Schiffer, B. (2013). The impact of alcohol dependence on social brain function. Addiction Biology, 18(1), 109-120.

Cabanis, M., Pyka, M., Mehl, S., Müller, B.W., Loos-Jankowiak, S., Winterer, G., Wölwer, W., Musso, F., Klingberg, S., Rapp, A.M., Langohr, K., Wiedemann, G., Herrlich, J., Walter, H., Wagner, M., Schnell, K., Vogeley, K., Kockler, H., Shah, N. J., Stöcker, T., Thienel, R., Pauly, K., Krug, A., & Kircher, T. (2013). The precuneus and the insula in self-attributional processes. Cogn Affekt Behav Neurosci, 13(2), 330-345.

2012

Frank J, Cichon S, Treutlein J, Ridinger M, Mattheisen M, Hoffmann P, Herms S, Wodarz N, Soyka M, Zill P, Maier W, Mössner R, Gaebel W, Dahmen N, Scherbaum N, Schmäl C, Steffens M, Lucae S, Ising M, Müller-Myhsok B, Nöthen MM, Mann K, Kiefer F, Rietschel M. Genome-wide significant association between alcohol dependence and a variant in the ADH gene cluster. Addict Biol. 2012;17(1): 171-80

Lenz B, Klafki HW, Hillemacher T, Frieling H, Clepce M, Gossler A, Thuerauf N, Winterer G, Kornhuber J, Bleich S. ERK1/2 protein and mRNA levels in human blood are linked to smoking behavior. Addict Biol. 2012;17(6): 1026-35

Rietschel M, Frank J, Cichon S, Treutlein J, Ridinger M, Soyka M, Scherbaum N, Noethen M, Mann K, Kiefer F. GENOMEWIDE ASSOCICATION STUDY IN ALCOHOL DEPENDENCE AND POLGYGENIC SCORE PREDICTION. Alcohol Clin Exp Res. 2012;36 2: 113A-113A

Schifano F, Martinotti G, Cunniff A, Reissner V, Scherbaum N, Ghodse H. Impact of an 18-month, NHS-based, treatment exposure for heroin dependence: results from the London Area Treat 2000 Study. Am J Addict. 2012;21(3): 268-73

Hamilton G, Harris SE, Davies G, Liewald DC, Tenesa A, Payton A, Horan MA, Ollier WE, Pendleton N, Genetic and Environmental Risk for Alzheimer's Disease (GERAD1) Consortium , Starr JM, Porteous D, Deary IJ, Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Chapman J, Russo G, Hamshere M, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown K, Passmore P, Craig D, McGuinness B, Todd S, Johnston J, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Heun R, Kölsch H, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate A, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Holmans P, O'Donovan M, Owen MJ, Williams J. The role of ECE1 variants in cognitive ability in old age and Alzheimer's disease risk. Am J Med Genet B Neuropsychiatr Genet. 2012;159B(6): 696-709

Koch P, Tamboli IY, Mertens J, Wunderlich P, Ladewig J, Stüber K, Esselmann H, Wiltfang J, Brüstle O, Walter J. Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of ß-secretase activity in endogenous amyloid-? generation. Am J Pathol. 2012;180(6): 2404-16

Zimmermann M, Grabemann M, Mette C, Abdel-Hamid M, Ueckermann J, Kraemer M, Wiltfang J, Kis B, Zepf FD. THE EFFECTS OF ACUTE TRYPTOPHAN DEPLETION ON REACTIVE AGGRESSION IN ADULTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) AND HEALTHY CONTROLS. Aust N Z J Psychiatry. 2012;46 1: 69-69

Svobodova Z, Reza Mohamadi M, Jankovicova B, Esselmann H, Verpillot R, Otto M, Taverna M, Wiltfang J, Viovy JL, Bilkova Z. Development of a magnetic immunosorbent for on-chip preconcentration of amyloid ß isoforms: Representatives of Alzheimer's disease biomarkers. Biomicrofluidics. 2012;6(2): 24126-2412612

Riss GL, Chang DI, Wevers C, Westendorf AM, Buer J, Scherbaum N, Hansen W. Opioid maintenance therapy restores CD4+ T cell function by normalizing CD4+CD25(high) regulatory T cell frequencies in heroin user. Brain Behav Immun. 2012;26(6): 972-8

Bibl M, Esselmann H, Wiltfang J. Neurochemical biomarkers in Alzheimer's disease and related disorders. Curr Alzheimer Res. 2012;5(6): 335-48

Genius J, Giegling I, Benninghoff J, Rujescu D. Disturbed function of GABAergic interneurons in schizophrenia: relevance for medical treatment? Curr Pharm Biotechnol. 2012;13(8): 1549-56

Rujescu D, Genius J, Benninghoff J, Giegling I. Current progress in the genetic research of schizophrenia: relevance for drug discovery? Curr Pharm Biotechnol. 2012;13(8): 1614-21

Chávez-Gutiérrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, Lismont S, Zhou L, Van Cleynenbreugel S, Esselmann H, Wiltfang J, Serneels L, Karran E, Gijsen H, Schymkowitz J, Rousseau F, Broersen K, De Strooper B. The mechanism of ß-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31(10): 2261-74

Bibl M, Welge V, Esselmann H, Wiltfang J. Stability of amyloid-? peptides in plasma and serum. Electrophoresis. 2012;33(3): 445-50

Genius J, Klafki H, Benninghoff J, Esselmann H, Wiltfang J. Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias. Eur Arch Psychiatry Clin Neurosci. 2012;262 Suppl : S71-7

Christiansen H, Kis B, Hirsch O, Matthies S, Hebebrand J, Uekermann J, Abdel-Hamid M, Kraemer M, Wiltfang J, Graf E, Colla M, Sobanski E, Alm B, Rösler M, Jacob C, Jans T, Huss M, Schimmelmann BG, Philipsen A. German validation of the Conners Adult ADHD Rating Scales (CAARS) II: Reliability, validity, diagnostic sensitivity and specificity. Eur Psychiatry. 2012;27(5): 321-8

Reissner V, Kokkevi A, Schifano F, Room R, Storbjörk J, Stohler R, Difuria L, Rehm J, Geyer M, Hölscher F, Scherbaum N. Differences in drug consumption, comorbidity and health service use of opioid addicts across six European urban regions (TREAT-project). Eur Psychiatry. 2012;27(6): 455-62

Bonnet U, Chang DI, Scherbaum N. Cannabis hyperemesis syndrome. Fortschr Neurol Psychiatr. 2012;80(2): 98-101

Bonnet U, Wiemann M. Neuropsychopharmaca influence the intracellular pH value of central neurons. Fortschr Neurol Psychiatr. 2012;80(4): 201-12

Dirks H, Esser S, Borgmann R, Wolter M, Fischer E, Potthoff A, Jablonka R, Schadendorf D, Brockmeyer N, Scherbaum N. Substance use and sexual risk behaviour among HIV-positive men who have sex with men in specialized out-patient clinics. HIV Med. 2012;13(9): 533-40

Corazza O, Schifano F, Simonato P, Fergus S, Assi S, Stair J, Corkery J, Trincas G, Deluca P, Davey Z, Blaszko U, Demetrovics Z, Moskalewicz J, Enea A, di Melchiorre G, Mervo B, di Furia L, Farre M, Flesland L, Pasinetti M, Pezzolesi C, Pisarska A, Shapiro H, Siemann H, Skutle A, Enea A, di Melchiorre G, Sferrazza E, Torrens M, van der Kreeft P, Zummo D, Scherbaum N. Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine. Hum Psychopharmacol. 2012;27(2): 145-9

Bibl M, Gallus M, Welge V, Esselmann H, Wiltfang J. Aminoterminally truncated and oxidized amyloid-ß peptides in the cerebrospinal fluid of Alzheimer's disease patients. J Alzheimers Dis. 2012;29(4): 809-16

Gerrish A, Russo G, Richards A, Moskvina V, Ivanov D, Harold D, Sims R, Abraham R, Hollingworth P, Chapman J, Hamshere M, Pahwa JS, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Johnston JA, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Kölsch H, Heun R, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Davies G, Harris SE, Starr JM, Deary IJ, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Jones L, Holmans PA, O'Donovan MC, Owen MJ, Williams J. The role of variation at AßPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis. 2012;28(2): 377-87

Bibl M, Welge V, Schmidt H, Esselmann H, Mollenhauer B, Lewczuk P, Otto M, Kornhuber J, Wiltfang J. Plasma amyloid-beta peptides in acute cerebral ischemia: a pilot study. J Clin Lab Anal. 2012;26(4): 238-45

Fischer E, Potthoff A, Scherbaum Norbert, Brockmeyer NH, Kompetenznetz HIV AIDS. Effects of the Viral Load Method on sexual Risk Behaviour and Risk Minimisation Strategies of MSM in HIV-Ambulances. J Dtsch Dermatol Ges. 2012;10 3: 38-38

Bibl M, Gallus M, Welge V, Esselmann H, Wolf S, Rüther E, Wiltfang J. Cerebrospinal fluid amyloid-ß 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. J Neural Transm. 2012;119(7): 805-13

Henkel AW, Müller K, Lewczuk P, Müller T, Marcus K, Kornhuber J, Wiltfang J. Multidimensional plasma protein separation technique for identification of potential Alzheimer's disease plasma biomarkers: a pilot study. J Neural Transm. 2012;119(7): 779-88

Haussmann U, Poetsch A. Global proteome survey of protocatechuate- and glucose-grown Corynebacterium glutamicum reveals multiple physiological differences. J Proteomics. 2012;75(9): 2649-59

Schuhmacher A, Becker T, Rujescu D, Quednow BB, Lennertz L, Wagner M, Benninghoff J, Rietschel M, Häfner H, Franke P, Wölwer W, Gaebel W, Maier W, Mössner R. Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics. J Psychiatr Res. 2012;46(8): 1073-80

Bonnet U, Scherbaum N. Craving dominates propofol addiction of an affected physician. J Psychoactive Drugs. 2012;44(2): 186-90

Genius J, Benninghoff J, Reuter N, Braun I, Giegling I, Hartmann A, Möller HJ, Rujescu D. Dysequilibrium of neuronal proliferation and apoptosis in a pharmacological animal model of psychosis. Methods. 2012;56(4): 519-27

Hollingworth P, Sweet R, Sims R, Harold D, Russo G, Abraham R, Stretton A, Jones N, Gerrish A, Chapman J, Ivanov D, Moskvina V, Lovestone S, Priotsi P, Lupton M, Brayne C, Gill M, Lawlor B, Lynch A, Craig D, McGuinness B, Johnston J, Holmes C, Livingston G, Bass NJ, Gurling H, McQuillin A, GERAD Consortium , National Institute on Aging Late-Onset Alzheimer's Disease Family Study Group , Holmans P, Jones L, Devlin B, Klei L, Barmada MM, Demirci FY, DeKosky ST, Lopez OL, Passmore P, Owen MJ, O'Donovan MC, Mayeux R, Kamboh MI, Williams J, Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere M, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown K, Passmore P, Craig D, McGuinness B, Todd S, Johnston J, Holmes C, Mann D, Smith A, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Heun R, Kölsch H, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate A, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz V, Younkin SG, Holmans P, O'Donovan M, Owen MJ, Williams J, Green R, Kowall N, Farrer L, Williamson J, Santana V, Schmechel D, Gaskel P, Ghetti B, Farlow MR, Horner K, Growdon JH, Blacker D, Tanzi RE, Hyman BT, Boeve B, Kuntz K, Norgaard L, Larson N, Kistler D, Parfitt F, Haddow J, Silverman J, Schnaider Beeri M, Sano M, Wang J, Lally R, Johnson N, Mesulum M, Weintraub S, Bigio E, Kaye J, Kramer P, Payne-Murphy J, Bennett D, Jacobs H, Chang JS, Arends D, Harrell L, Bartzokis G, Cummings J, Lu PH, Toland U, Smith C, Brickhouse A, Trojanowski J, Van Deerlin V, McCarty Wood E, Lopez OL, Sweet RA, Chui IH, Varpetian A, Diaz-Arrastia R, Rosenberg R, Davis B, Bird T, Rumbaugh M, Schellenberg GD, Raskind M, Goate A, Morris J, Norton J, Levitch D, Grant B, Coats M. Genome-wide association study of Alzheimer's disease with psychotic symptoms. Mol Psychiatry. 2012;17(12): 1316-27

Fiedler U, Wiltfang J, Peters N, Benninghoff J. Advances in the diagnostics of Alzheimer's disease. Nervenarzt. 2012;83(5): 661-73

Hamilton G, Killick R, Genetic and Environmental Risk for Alzheimer's Disease Consortium , Translational Genomics Research Institute Consortium , Lambert JC, Amouyel P, European Alzheimer Disease Initiative , Carrasquillo MM, Pankratz VS, Graff-Radford NR, Dickson DW, Petersen RC, Younkin SG, Powell JF, Wade-Martins R, Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Chapman J, Russo G, Hamshere M, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown K, Passmore P, Craig D, McGuinness B, Todd S, Johnston J, Holmes C, Mann D, Smith A, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Heun R, Kölsch H, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate A, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Holmans P, O'Donovan M, Owen MJ, Williams J, Myers AJ, Hardy JA, Morrison-Bogorad M, Phelps T, Kukull W, Seemann R, Troncoso JC, Pletnikova O, Vinters H, Pomakian J, Hulette C, Ervin JF, Horoupian D, Salehi A, Vonsattel JP, Mancevska K, Hedley-Whyte E, Frosch MP, Fitch K, Albin R, Bain L, Gombosi E, Markesbery W, Anderson S, Dickson DW, Thomas N, Miller CA, Tang J, Diaz D, McKeel D, Morris JC, Johnson E, Buckles V, Carter D, Montine T, Schantz A, Trojanowski JQ, Lee VM, Van Deerlin V, Schuck T, McKee AC, Rogers J, Beach TG, Wainer BH, Gearing M, White CL, Rosenberg R, Howell M, Reisch J, Ellis W, Jarvis MA, Bennett DA, Schneider MD, Skish K, Longman WT, Mash DC, Basile MJ, Wotljer R, Morris CM, McKeith IG, Perry RH, Lovestone S, Al-Sarraj S, Troakes C, Love S, Kehoe P, Palmer L, Huitinga I, Rademaker M, Kooreman M, Abizanda IF, Boluda SC, Corneveaux JJ, Myers AJ, Hardy J, Reiman EM, Huentelman MJ, Hannequin D, Pasquier F, Epelbaum J, Berr C, Dartigues JF, Tzourio C, Campion D, Alpérovitch A, Carrasquillo MM, Zou F, Pankratz V, Wilcox SL, Walker LP, Younkin SG, Younkin CS, Younkin LH, Bisceglio GD, Ertekin-Taner N, Crook JE, Dickson DW, Petersen RC, Graff-Radford NR, Younkin SG. Functional and genetic analysis of haplotypic sequence variation at the nicastrin genomic locus. Neurobiol Aging. 2012;33(8): 1848.e1-13

Koch W, Teipel S, Mueller S, Benninghoff J, Wagner M, Bokde AL, Hampel H, Coates U, Reiser M, Meindl T. Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease. Neurobiol Aging. 2012;33(3): 466-78

Shi H, Belbin O, Medway C, Brown K, Kalsheker N, Carrasquillo M, Proitsi P, Powell J, Lovestone S, Goate A, Younkin S, Passmore P, Genetic and Environmental Risk for Alzheimer's Disease Consortium , Morgan K, Alzheimer's Research UK Consortium , Harold D, Sims R, Gerrish A, Chapman J, Moskvina V, Abraham R, Hollingworth P, Hamshere M, Pahwa JS, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown K, Passmore P, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith A, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Heun R, Kölsch H, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate A, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Nöthen MM, Holmans P, O'Donovan M, Owen MJ, Williams J. Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiol Aging. 2012;33(8): 1849.e5-18

Hudson G, Sims R, Harold D, Chapman J, Hollingworth P, Gerrish A, Russo G, Hamshere M, Moskvina V, Jones N, Thomas C, Stretton A, Holmans PA, O'Donovan MC, Owen MJ, Williams J, Chinnery PF, GERAD1 Consortium , Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Chapman J, Russo G, Hamshere M, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown K, Passmore P, Craig D, McGuinness B, Todd S, Johnston J, Holmes C, Mann D, Smith A, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Heun R, Kölsch H, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate A, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Holmans P, O'Donovan M, Owen MJ, Williams J. No consistent evidence for association between mtDNA variants and Alzheimer disease. Neurology. 2012;78(14): 1038-42

Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgruber S, Jessen F, Popp J, Maier W, Hüll M, Frölich L, Hampel H, Perneczky R, Peters O, Jahn H, Luckhaus C, Gertz HJ, Schröder J, Pantel J, Lewczuk P, Kornhuber J, Wiltfang J. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology. 2012;78(6): 379-86

Linning P, Haussmann U, Beyer I, Weidlich S, Schieb H, Wiltfang J, Klafki HW, Knölker HJ. Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - development of potential agents for the treatment of Alzheimer's disease. Org Biomol Chem. 2012;10(41): 8216-35

Genius J, Geiger J, Bender A, Möller HJ, Klopstock T, Rujescu D. Creatine protects against excitoxicity in an in vitro model of neurodegeneration. PLoS ONE. 2012;7(2): e30554

Jesse S, Lehnert S, Jahn O, Parnetti L, Soininen H, Herukka SK, Steinacker P, Tawfik S, Tumani H, von Arnim CA, Neumann M, Kretzschmar HA, Kulaksiz H, Lenter M, Wiltfang J, Ferger B, Hengerer B, Otto M. Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementia. PLoS ONE. 2012;7(11): e48783

Schlaak JF, Trippler M, Hoyo-Becerra C, Erim Y, Kis B, Wang B, Scherbaum N, Gerken G. Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy. PLoS ONE. 2012;7(6): e38668

Zimmermann M, Grabemann M, Mette C, Abdel-Hamid M, Uekermann J, Ueckermann J, Kraemer M, Wiltfang J, Kis B, Zepf FD. The effects of acute tryptophan depletion on reactive aggression in adults with attention-deficit/hyperactivity disorder (ADHD) and healthy controls. PLoS ONE. 2012;7(3): e32023

Deluca P, Davey Z, Corazza O, Di Furia L, Farre M, Flesland LH, Mannonen M, Majava A, Peltoniemi T, Pasinetti M, Pezzolesi C, Scherbaum N, Siemann H, Skutle A, Torrens M, van der Kreeft P, Iversen E, Schifano F. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(2): 221-6

Bibl M, Gallus M, Welge V, Lehmann S, Sparbier K, Esselmann H, Wiltfang J. Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-ß peptides. Proteomics Clin Appl. 2012;6(3-4): 163-9

Schrijvers EM, Schürmann B, Koudstaal PJ, van den Bussche H, Van Duijn CM, Hentschel F, Heun R, Hofman A, Jessen F, Kölsch H, Kornhuber J, Peters O, Rivadeneira F, Rüther E, Uitterlinden AG, Riedel-Heller S, Dichgans M, Wiltfang J, Maier W, Breteler MM, Ikram MA. Genome-wide association study of vascular dementia. Stroke. 2012;43(2): 315-9

Uehara T, Itoh H, Matsuoka T, Rujescu D, Genius J, Seo T, Sumiyoshi T. Effect of transient blockade of N-methyl-D-aspartate receptors at neonatal stage on stress-induced lactate metabolism in the medial prefrontal cortex of adult rats: role of 5-HT1A receptor agonism. Synapse. 2012;66(5): 408-17

Benninghoff J, van der Ven A, Schloesser RJ, Moessner R, Möller HJ, Rujescu D. The complex role of the serotonin transporter in adult neurogenesis and neuroplasticity. A critical review. World J Biol Psychiatry. 2012;13(4): 240-7

Schiffer, B., Leygraf, N., Müller, B.W., Scherbaum, N., Forsting, M., Wiltfang, J., Gizewski, E., Hodgins, S. (2012). Structural brain alterations associated with schizophrenia preceded by conduct disorder: A common and distinct subtype of schizophrenia? Schizophrenia Bulletin, in press.

Gizewski, E., Müller, B., Scherbaum, N., Lieb, B., Forsting, M., Wiltfang, J., Leygraf, N., Schiffer, B. (2012). The impact of alcohol dependence on social brain function. Addiction Biology, in press.

2011 

Bonnet U, Lensing M, Specka M, Scherbaum N. Comparison of two oral symptom-triggered pharmacological inpatient treatments of acute alcohol withdrawal: clomethiazole vs. clonazepam. Alcohol Alcohol. 2011;46(1): 68-73

Verpillot R, Esselmann H, Mohamadi MR, Klafki H, Poirier F, Lehnert S, Otto M, Wiltfang J, Jean Louis V, Taverna M. Analysis of amyloid-ß peptides in cerebrospinal fluid samples by capillary electrophoresis coupled with LIF detection. Anal Chem. 2011;83(5): 1696-703

Schiffer B, Müller BW, Scherbaum N, Hodgins S, Forsting M, Wiltfang J, Gizewski ER, Leygraf N. Disentangling structural brain alterations associated with violent behavior from those associated with substance use disorders. Arch Gen Psychiatry. 2011;68(10): 1039-49

Frings L, Klöppel S, Teipel S, Peters O, Frölich L, Pantel J, Schröder J, Gertz HJ, Arlt S, Heuser I, Kornhuber J, Wiltfang J, Maier W, Jessen F, Hampel H, Hüll M. Left anterior temporal lobe sustains naming in Alzheimer's dementia and mild cognitive impairment. Curr Alzheimer Res. 2011;8(8): 893-901

Corazza O, Schifano F, Farre M, Deluca P, Davey Z, Torrens M, Demetrovics Z, Di Furia L, Flesland L, Siemann H, Skutle A, Van Der Kreeft P, Scherbaum N. Designer drugs on the internet: a phenomenon out-of-control? the emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol. 2011;6(2): 125-9

Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Otto M, Kornhuber J, Rüther E, Wiltfang J. Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-ß(38/40/42) in Frontotemporal Dementias and Primary Progressive Aphasias. Dement Geriatr Cogn Disord. 2011;31(1): 37-44

Wölwer W, Frommann N, Jänner M, Franke PE, Scherbaum N, Lieb B, Falkai P, Wobrock T, Kuhlmann T, Radermacher M, Maier W, Schütz C, Ohmann C, Burtscheidt W, Gaebel W. The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial. Drug Alcohol Depend. 2011;118(2-3): 417-22

Specka M, Buchholz A, Kuhlmann T, Rist F, Scherbaum N. Prediction of the outcome of inpatient opiate detoxification treatment: results from a multicenter study. Eur Addict Res. 2011;17(4): 178-84

Lennertz L, Quednow BB, Benninghoff J, Wagner M, Maier W, Mossner R. Impact of TCF4 on the genetics of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2011;261 2: 161-165

Wiltfang J. Clinical neuroproteomics and biomarkers of Alzheimer's disease. Eur Neuropsychopharmacol. 2011;21 3: S187-S187

Christiansen H, Kis B, Hirsch O, Philipsen A, Henneck M, Panczuk A, Pietrowsky R, Hebebrand J, Schimmelmann BG. German validation of the Conners Adult ADHD Rating Scales-self-report (CAARS-S) I: factor structure and normative data. Eur Psychiatry. 2011;26(2): 100-7

Bonnet U. Assessment of the addictive risk of propofol. Fortschr Neurol Psychiatr. 2011;79(8): 442-52

Specka M, Böning A, Scherbaum N. Contingency management in opioid substitution treatment. Fortschr Neurol Psychiatr. 2011;79(7): 395-403

Ruhl M, Knuschke T, Schewior K, Glavinic L, Neumann-Haefelin C, Chang DI, Klein M, Heinemann FM, Tenckhoff H, Wiese M, Horn PA, Viazov S, Spengler U, Roggendorf M, Scherbaum N, Nattermann J, Hoffmann D, Timm J, East German HCV Study Group. CD8(+) T-cell response promotes evolution of hepatitis C virus nonstructural proteins. Gastroenterology. 2011;140(7): 2064-73

Schmidt CS, Schulte B, Gansefort D, Goelz J, Gerken G, Scherbaum N, Jochum C, Verthein U, Backmund M, Reimer J. OPTIMIZING HCV THERAPY: THE IMPACT OF PSYCHOEDUCATION ON RETENTION AND SVR IN OPIATE SUBSTITUTED PATIENTS. Hepatology. 2011;54 1: 821A-822A

Specka M, Bonnet U, Heilmann M, Schifano F, Scherbaum N. Longitudinal patterns of benzodiazepine consumption in a German cohort of methadone maintenance treatment patients. Hum Psychopharmacol. 2011;26(6): 404-411

Spitzer P, Schieb H, Kamrowski-Kruck H, Otto M, Chiasserini D, Parnetti L, Herukka SK, Schuchhardt J, Wiltfang J, Klafki HW. Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia. Int J Alzheimers Dis. 2011;2011: 739847

Drago V, Babiloni C, Bartres-Faz D, Caroli A, Bosch B, Hensch T, Didic M, Klafki HW, Pievani M, Jovicich J, Venturi L, Spitzer P, Vecchio F, Schoenknecht P, Wiltfang J, Redolfi A, Forloni G, Blin O, Irving E, Davis C, Hardemark HG, Frisoni GB. Disease Tracking Markers for Alzheimer's Disease at the prodromal (MCI) Stage. J Alzheimers Dis. 2011;26 3: 159-199

Jessen F, Lewczuk P, Gür O, Block W, Ende G, Frölich L, Hammen T, Arlt S, Kornhuber J, Kucinski T, Popp J, Peters O, Maier W, Träber F, Wiltfang J. Association of N-acetylaspartate and cerebrospinal fluid Aß42 in dementia. J Alzheimers Dis. 2011;27(2): 393-9

Mollenhauer B, Esselmann H, Trenkwalder C, Schulz-Schaeffer W, Kretzschmar H, Otto M, Wiltfang J, Bibl M. CSF amyloid-ß peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease. J Alzheimers Dis. 2011;24(2): 383-91

Schipke CG, Jessen F, Teipel S, Luckhaus C, Wiltfang J, Esselmann H, Frölich L, Maier W, Rüther E, Heppner FL, Prokop S, Heuser I, Peters O. Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid. J Alzheimers Dis. 2011;26(2): 255-62

Urraca JL, Aureliano CS, Schillinger E, Esselmann H, Wiltfang J, Sellergren B. Polymeric complements to the Alzheimer's disease biomarker ß-amyloid isoforms Aß1-40 and Aß1-42 for blood serum analysis under denaturing conditions. J Am Chem Soc. 2011;133(24): 9220-3

Schieb H, Kratzin H, Jahn O, Möbius W, Rabe S, Staufenbiel M, Wiltfang J, Klafki HW. Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloid. J Biol Chem. 2011;286(39): 33747-58

Mollenhauer B, Esselmann H, Roeber S, Schulz-Schaeffer WJ, Trenkwalder C, Bibl M, Steinacker P, Kretzschmar HA, Wiltfang J, Otto M. Different CSF beta-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease (vol 118, pg 691, 2011). J Neural Transm. 2011;118(8): 1261-1262

Mollenhauer B, Esselmann H, Roeber S, Schulz-Schaeffer WJ, Trenkwalder C, Bibl M, Steinacker P, Kretzschmar HA, Wiltfang J, Otto M. Different CSF ß-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease. J Neural Transm. 2011;118(5): 691-7

Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O, Florbetaben Study Group , Ehret R, Drzezga A, Krause B, Kurz A, Bartenstein P, Rujescu D, Buerger K, Kotzerke J, Bauer M, Kuwert T, Kornhuber J, Bockisch A, Diener HC, Wiltfang J, Dresel S, Heuser I, Peters O, Schober O, Fey T, Bauer A, Maier W, Buck A, Hock C, van Dyck C, Carson RE, Jennings D, Seibyl J, De Santi S, Friedman K, Steinerman JR, Blaufox D, Sabri O, Rowe C, Woodward M, Chatterton B, Prowse RJ, Larcos G, Purcell R, Sabri O, Barthel H, Gertz HJ. Cerebral amyloid-ß PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5): 424-35

Ott S, Henkel AW, Henkel MK, Redzic ZB, Kornhuber J, Wiltfang J. Pre-aggregated Aß1-42 peptide increases tau aggregation and hyperphosphorylation after short-term application. Mol Cell Biochem. 2011;349(1-2): 169-77

Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Rüther E, Schürmann B, Heun R, Kölsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Gallacher J, Hüll M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, Alzheimer's Disease Neuroimaging Initiative , van Duijn CM, Breteler MM, Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S, CHARGE consortium , Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alpérovitch A, Lathrop M, EADI1 consortium , Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Björnsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossù P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43(5): 429-35

Kraemer M, Haertig S, Hill A, Uekermann J, Wiltfang J, Kis B. Huntington's chorea mimicking adult attention deficit hyperactivity disorder. Nervenarzt. 2011;82(3): 360-2

Hermann DM, Keyvani K, van de Nes J, Weimar C, Wiltfang J, Nitsch RM, Szodorai A. Brain-reactive ß-amyloid antibodies in primary CNS angiitis with cerebral amyloid angiopathy. Neurology. 2011;77(5): 503-5

Hagemann G, Ugur T, Schleussner E, Mentzel HJ, Fitzek C, Witte OW, Gaser C. Changes in brain size during the menstrual cycle. PLoS ONE. 2011;6(2): e14655

Bachmann HS, Lieb B, Bonnet U, Specka M, Augener S, Siffert W, Scherbaum N. Influence of the 393T>C polymorphism of the GNAS1 gene on the intensity of opiate withdrawal. Pharmacopsychiatry. 2011;44(4): 159-60

Specka M, Lieb B, Kuhlmann T, Frommann N, Wobrock T, Schifano F, Gaebel W, Scherbaum N. Marked reduction of heavy drinking did not reduce nicotine use over 1 year in a clinical sample of alcohol-dependent patients. Pharmacopsychiatry. 2011;44(3): 120-1

Albaum SP, Hahne H, Otto A, Haußmann U, Becher D, Poetsch A, Goesmann A, Nattkemper TW. A guide through the computational analysis of isotope-labeled mass spectrometry-based quantitative proteomics data: an application study. Proteome Sci. 2011;9(1): 30

Gröttrup B, Böckmann M, Marcus K, Wiltfang J, Grinberg LT, Meyer HE, Park YM. Clinical aspects of neurodegenerative diseases - 15th HUPO BPP Workshop April 8-9, 2011, Bochum, Germany. Proteomics. 2011;11(22): 4279-83

Gröttrup B, Stephan C, Marcus K, Grinberg LT, Wiltfang J, Lee SK, Kim YH, Meyer HE, Park YM. Creating a human brain proteome atlas--13th HUPO BPP Workshop March 30-31, 2010, Ochang, Korea. Proteomics. 2011;11(14): 2759-62

Poetsch A, Haussmann U, Burkovski A. Proteomics of corynebacteria: From biotechnology workhorses to pathogens. Proteomics. 2011;11(15): 3244-55

Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, Davey Z, Corkery J, Siemann H, Scherbaum N, Farre' M, Torrens M, Demetrovics Z, Ghodse AH, Psychonaut Web Mapping , ReDNet Research Groups. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berl). 2011;214(3): 593-602

Schifano F, D'Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, Di Melchiorre G, Di Furia L, Farré M, Flesland L, Mannonen M, Majava A, Pagani S, Peltoniemi T, Siemann H, Skutle A, Torrens M, Pezzolesi C, van der Kreeft P, Scherbaum N. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80(2): 118-22

Teipel SJ, Peters O, Heuser I, Jessen F, Maier W, Froelich L, Arlt S, Hull M, Gertz HJ, Kornhuber J, Wiltfang J, Thome J, Rienhoff O, Meindl T, Hampel H, Grothe M. Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: Effect of different processing and analysis approaches on sample sizes. World J Biol Psychiatry. 2011;12 1: 109-113

Christiansen H / Kis B, Hirsch O, Matthis S, Hebebrand J, Uekermann J, Abdel-Hamid M, Kraemer M, Wiltfang J, Graf E, Colla M, Sobanski E, Alm B, Rösler M, Jacob C, Jans T, Huss M, Schimmelmann BG, Philipsen A. German validation of the Conners Adult ADHD Rating Scales (CAARS) II: Reliability, validity, diagnostic sensitivity and specificity. Eur Psychiatry 2011 Mar 8. [Epub ahead of print]. (the first two authors contributed equally to this work)

Christiansen H / Kis B, Hirsch O, Philipsen A, Henneck M, Panczuk A, Pietrowsky R, Hebebrand J, Schimmelmann BG. German validation of the Conners Adult ADHD Rating Scales - self-report (CAARS-S) I: Factor structure and normative data. Eur Psychiatry 2011,26;100-107. (the first two authors contributed equally to this work)

Krämer M, Härtig S, Hill A, Uekermann J, Wiltfang J, Kis B. Erstmanifestation einer Chorea Huntington unter dem klinischen Bild einer adulten Aufmerksamkeits-Defizit-Hyperaktivitätsstörung (Chorea Huntington mimicking adult attention deficit hyperactivity disorder). Nervenarzt 2011,82;360-362.

Schiffer, B., Müller, B. W., Scherbaum, N., Gizewski, E., Forsting, M., Hodgins, S., Wiltfang, J., & Leygraf, N. (2011). Disentangling structural brain alterations associated with violent offending from those associated with substance use disorders. Archives of General Psychiatry, 68(10), 1039-1049.

Georg Hagemann, Tarik Ugur, Ekkehard Schleussner, Hans-Joachim Mentzel,Clemens Fitzek, Otto Witte, and Christian Gaser (2011): Changes in Brain Size during the menstrual cycle PlosOne

2010 

Bonnet U, Hamzavi-Abedi R, Specka M, Wiltfang J, Lieb B, Scherbaum N. An open trial of gabapentin in acute alcohol withdrawal using an oral loading protocol. Alcohol Alcohol. 2010;45(2): 143-5.

Treutlein J, Cichon S, Ridinger M, Wodarz N, Soyka M, Maier W, Moessner R, Dahmen N, Fehr C, Scherbaum N, Wichmann E, Schreiber S, Dragano N, Sommer WH, Wienker T, Sullivan PF, Nothen M, Kiefer F, Spanagel R, Mann KF, Rietschel M. GENOME-WIDE ASSOCIATION STUDY OF ALCOHOL DEPENDENCE. Alcohol Clin Exp Res. 2010;34(8): 43A-43A.

Microchip electrophoresis profiling of Aß peptides in the cerebrospinal fluid of patients with Alzheimer's disease. Anal Chem. 2010;82(18): 7611-7. Mohamadi MR, Svobodova Z, Verpillot R, Esselmann H, Wiltfang J, Otto M, Taverna M, Bilkova Z, Viovy JL

Maier C, Iwunna J, Soukup J, Scherbaum N . Addicted anaesthetists. Anasthesiol Intensivmed Notfallmed Schmerzther. 2010;45(10): 648-54; quiz 655

Ansermot N, Albayrak O, Schläpfer J, Crettol S, Croquette-Krokar M, Bourquin M, Déglon JJ, Faouzi M, Scherbaum N, Eap CB. Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval. Arch Intern Med. 2010;170(6): 529-36

Bonnet U, Bingmann D, Wiltfang J, Scherbaum N, Wiemann M. Modulatory effects of neuropsychopharmaca on intracellular pH of hippocampal neurones in vitro. Br J Pharmacol. 2010;159(2): 474-83

Schiffer B, Müller BW, Scherbaum N, Forsting M, Wiltfang J, Leygraf N, Gizewski ER. Impulsivity-related brain volume deficits in schizophrenia-addiction comorbidity. Brain. 2010;133(10): 3093-103

Schieb H, Weidlich S, Schlechtingen G, Linning P, Jennings G, Gruner M, Wiltfang J, Klafki HW, Knölker HJ. Structural design, solid-phase synthesis and activity of membrane-anchored ß-secretase inhibitors on Aß-generation from wild-type and Swedish-mutant APP. Chemistry. 2010;16(48): 14412-23

Langenbach T, Spönlein A, Overfeld E, Wiltfang G, Quecke N, Scherbaum N, Melchers P, Hebebrand J. Axis I comorbidity in adolescent inpatients referred for treatment of substance use disorders. Child Adolesc Psychiatry Ment Health. 2010;4: 25

Kraemer M, Uekermann J, Wiltfang J, Kis B. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clin Neuropharmacol. 2010;33(4): 204-6

Hölscher F, Reissner V, Di Furia L, Room R, Schifano F, Stohler R, Yotsidi V, Scherbaum N. Differences between men and women in the course of opiate dependence: is there a telescoping effect? Eur Arch Psychiatry Clin Neurosci. 2010;260(3): 235-41

Specka M, Buchholz A, Kuhlmann T, Haasen C, Scherbaum N. Outcome of inpatient opiate detoxification treatment in immigrants as compared to native Germans. Eur Psychiatry. 2010;25(4): 242-8

Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Bürger K, Hampel H, Frölich L, Henn F, Falkai P, Rüther E, Jahn H, Luckhaus C, Perneczky R, Schmidtke K, Schröder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol. 2010;223(2): 366-70

Bonnet U, Scherbaum N. Cannabis use disorders. Fortschr Neurol Psychiatr. 2010;78(5): 297-302; quiz 303-5

Bonnet U, Chang DI, Wiltfang J, Scherbaum N, Weber R. A case of cannabis-induced mania. Fortschr Neurol Psychiatr. 2010;78(4): 223-5

Bonnet U, Scherbaum N. Cannabis use disorders. Part II: Psychiatric and somatic sequelae and comorbidities. Fortschr Neurol Psychiatr. 2010;78(6): 360-7; quiz 368

Bibl M, Esselmann H, Lewczuk P, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J, Mollenhauer B. Combined Analysis of CSF Tau, Aß42, Aß-42% and Aß1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia. Int J Alzheimers Dis. 2010;2010

Parnetti L, Wiltfang J, Blennow K. Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease? Int J Alzheimers Dis. 2010;2010: 293587

Spitzer P, Klafki HW, Blennow K, Buée L, Esselmann H, Herruka SK, Jimenez C, Klivenyi P, Lewczuk P, Maler JM, Markus K, Meyer HE, Morris C, Müller T, Otto M, Parnetti L, Soininen H, Schraen S, Teunissen C, Vecsei L, Zetterberg H, Wiltfang J. cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. Int J Alzheimers Dis. 2010;2010

Alexopoulos P, Kurz A, Lewczuk P, Kornhuber J, Wiltfang J, Maier W, Förstl H, Perneczky R. The sortilin-related receptor SORL1 and the amyloid cascade: a possible explanation for the concurrent elevation of CSF soluble APPalpha and APPbeta in Alzheimer's disease. Int J Geriatr Psychiatry. 2010;25(5): 542-3

Lenz B, Klafki HW, Hillemacher T, Killisch N, Schaller G, Frieling H, Clepce M, Gossler A, Thuerauf N, Winterer G, Kornhuber J, Bleich S. Smoking behaviour is associated with expression and phosphorylation of CREB in human buffy coat. Int J Neuropsychopharmacol. 2010;13(2): 207-15

Steinacker P, Klafki H, Lehnert S, Jesse S, Arnim CA, Tumani H, Pabst A, Kretzschmar HA, Wiltfang J, Otto M. ERK2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. J Alzheimers Dis. 2010;22(1): 119-28

Zimmermann R, Beck G, Knispel S, Maler JM, Weih M, Wiltfang J, Kornhuber J, Lewczuk P. Intrathecal IgG synthesis in patients with alterations in the neurochemical dementia diagnostics. J Alzheimers Dis. 2010;19(4): 1199-203

Schmidt D, Zimmermann R, Lewczuk P, Schaller G, Degirmenci U, Kreil S, Wiltfang J, Kuwert T, Kornhuber J, Weih M. Confirmation rate of blinded (99m)Tc-SPECT compared to neurochemical dementia biomarkers in CSF in patients with Alzheimer disease. J Neural Transm. 2010;117(9): 1111-4

Spitzer P, Herrmann M, Klafki HW, Smirnov A, Lewczuk P, Kornhuber J, Wiltfang J, Maler JM. Phagocytosis and LPS alter the maturation state of ß-amyloid precursor protein and induce different Aß peptide release signatures in human mononuclear phagocytes. J Neuroinflammation. 2010;7: 59

Ebert S, Goos M, Rollwagen L, Baake D, Zech WD, Esselmann H, Wiltfang J, Mollenhauer B, Schliebs R, Gerber J, Nau R. Recurrent systemic infections with Streptococcus pneumoniae do not aggravate the course of experimental neurodegenerative diseases. J Neurosci Res. 2010;88(5): 1124-36

Bohoyo D, Le Potier I, Rivière C, Klafki H, Wiltfang J, Taverna M. A quantitative CE method to analyse tau protein isoforms using coated fused silica capillaries. J Sep Sci. 2010;33(8): 1090-8

Martin R, Kirst J, Weidlich S, Schieb H, Schlechtingen G, Jager A, Rajendran L, Bohl M, Richter S, Fedorov R, Manstein DJ, Gutzeit HO, Klafki H, Wiltfang J, Simons K, Knolker HJ. BIOMOLECULAR CHEMISTRY DIRECTED TOWARDS DRUG DEVELOPMENT. Med Chem Res. 2010;19: S23-S26

Vieira SI, Rebelo S, Esselmann H, Wiltfang J, Lah J, Lane R, Small SA, Gandy S, da Cruz E Silva EF, da Cruz E Silva OA. Retrieval of the Alzheimer's amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated. Mol Neurodegener. 2010;5: 40

Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Bürger K, Hampel H, Frölich L, Wolf S, Prinz B, Jahn H, Luckhaus Ch, Perneczky R, Hüll M, Schröder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kölsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.. Mol Psychiatry. 2010;15(2): 138-45

Bachmann HS, Lieb B, Bonnet U, Specka M, Augener S, Scherbaum N, Siffert W. The T-allele of the GNB3 825C > T polymorphism is associated with increased intensity of opiate withdrawal Naunyn Schmiedebergs Arch Pharmacol. 2010;381: 87-87

Cohen S, Kühn KU, Sträter B, Scherbaum N, Weig W. Adverse side-effect on sexual function caused by psychotropic drugs and psychotropic substances.  Nervenarzt. 2010;81(9): 1129-37; quiz 1138

Uekermann J, Kraemer M, Abdel-Hamid M, Schimmelmann BG, Hebebrand J, Daum I, Wiltfang J, Kis B. Social cognition in attention-deficit hyperactivity disorder (ADHD). Neurosci Biobehav Rev. 2010;34(5): 734-43

Schnaudigel S, Preul C, Ugur T, Mentzel HJ, Witte OW, Tittgemeyer M, Hagemann G. Positional brain deformation visualized with magnetic resonance morphometry. Neurosurgery. 2010;66(2): 376-84; discussion 384

Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, van den Bussche H, Heuser I, Peters O, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Rüther E, Carrasquillo MM, Pankratz VS, Younkin SG, Hardy J, O'Donovan MC, Owen MJ, Williams J. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS ONE. 2010;5(11): e13950

Schieb H, Spitzer P, Riess V, Wiltfang J, Klafki HW. A method to prevent cross contamination during 2-DE by ß-amyloid peptides. Proteomics. 2010;10(19): 3539-43

Steinacker P, Rist W, Swiatek-de-Lange M, Lehnert S, Jesse S, Pabst A, Tumani H, von Arnim CA, Mitrova E, Kretzschmar HA, Lenter M, Wiltfang J, Otto M. Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease. Proteomics. 2010;10(1): 81-9

Teipel SJ, Ewers M, Wolf S, Jessen F, Kölsch H, Arlt S, Luckhaus C, Schönknecht P, Schmidtke K, Heuser I, Frölich L, Ende G, Pantel J, Wiltfang J, Rakebrandt F, Peters O, Born C, Kornhuber J, Hampel H. Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. Psychiatry Res Neuroimaging. 2010;182(3): 244-50)

Loos S, Kargel C, Martinez U, Hesse A, Musso F, Brinkmeyer J, Winterer G, Klingberg S, Kircher T, Sartory G, Wiltfang J, Muller BW. MATCH AND MISMATCH IN AUDITORY FEEDBACK TO SPOKEN WORDS. AN FMRI STUDY. Schizophr Res. 2010;117(2-3): 356-357

Schiffer B, Muller BW, Gizewski ER. COGNITION AND IMPULSIVITY RELATED BRAIN VOLUME CHANGES IN SCHIZOPHRENIA-ADDICTION CO-MORBIDITY. Schizophr Res. 2010;117(2-3): 425-425

Scherbaum N, Specka M, Schifano F, Bombeck J, Marrziniak B. Longitudinal observation of a sample of German drug consumption facility clients. Subst Use Misuse. 2010;45(1-2): 176-89

Klingberg S, Wittorf A, Meisner C, Wölwer W, Wiedemann G, Herrlich J, Bechdolf A, Müller BW, Sartory G, Wagner M, Kircher T, König HH, Engel C, Buchkremer G. Cognitive behavioural therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: the POSITIVE Study, a multicenter, prospective, single-blind, randomised controlled clinical trial. Trials. 2010;11: 123

Uekermann J, Kraemer M, Abdel-Hamid M, Schimmelmann BG, Hebebrand J, Daum I, Kis B. Social cognition in attention-deficit hyperactivity disorder (ADHD). Neuroscience & Biobehavioral Reviews 2010,34;734-743.

Schnaudigel S, Preul C, Ugur T, Mentzel HJ, Witte OW, Tittgemeyer M, Hagemann G.: Positional brain deformation visualized with magnetic resonance morphometry. Neurosurgery. 2010 Feb;66(2):376-84; discussion 384

Philipsen A, Graf E, Tebartz van Elst L, Jans T, Warnke A, Hesslinger B, Ihorst G, Lesch KP, Gerlach M, Matthies S, Colla M, Jacob C, Sobanski E, Alm B, Rösler M, Kis B, Huss M, Lieb K, Schlander M, Berger M. Evaluation of the Efficacy and Effectiveness of a Structured Disorder Tailored Psychotherapy in ADHD in Adults - Study Protocol of a Randomized Controlled Multicentre Trial (COMPAS), ADHD Attention Deficit and Hyperactivity Disorders 2010,2;203-212 .

Stein, E. M, Loos, S. Schneider, A., Esselmann, H., Hesse A., Ennen, J., Schade-Brittinger, C., Abu-Omar, K. Hinrichs, T., Niedermeier, M., Moos, E., Weide, K., Trampisch, H.-J., Platen, P., Rütten, A.,  Wiltfang, J., Müller, B.W. (2011). Regelmäßige körperliche Aktivität als nichtpharmakologischer präventions- und Behandlungsansatz im Frühstadium der Alzheimer-Demenz. NeuroGeriatrie, 8(1): 1-4.

Stein, E. M., Loos, S., Schneider, A., Esselmann, H., Hesse, A., Ennen, J., Schade-Brittinger, C., Abu-Omar, K., Hinrichs, T., Niedermeier, M., Moos, E., Weide, K., Trampisch, H. J., Platen, P., Rütten, A., Wiltfang, J., & Müller, B. W. (2010). Regelmäßige körperliche Aktivität als nichtpharmakologischer Präventions- und Behandlungsansatz im Frühstadium der Alzheimer-Demenz (The effectiveness of regular physical activity and exercise in the prevention and treatment of cognitive impairment and early
Alzheimer's Disease). Neurologie & Rehabilitation, 16(5), 247-250.

Klingberg, S., Wittorf, A., Meisner, C., Wolwer, W., Wiedemann, G., Herrlich, J., Bechdolf, A., Mueller, B. W., Sartory, G., Wagner, M., Kircher, T., Koenig, H. H., Engel, C., & Buchkremer, G. (2010). Cognitive behavioural therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: The POSITIVE Study, a multicenter, prospective, single-blind, randomised controlled clinical trial. Trials, 11, 123.

Krämer M, Uekermann J, Wiltfang J, Kis B. Methylphenidate-induced psychosis in adult attention deficit hyperactivity disorder – Report of three new cases and review of the literature. Clin Neuropharmacol 2010,33;204-6.

Wittorf, A., Jakobi, U., Bannert, K. H., Bechdolf, A., Muller, B.W., Sartory, G., et al. (2010). Does the cognitive dispute of psychotic symptomsdo harm to the therapeutic alliance. Journal of Nervous and Mental Disease.

2009

Maler JM, Spitzer P, Klafki HW, Esselmann H, Lewczuk P, Kornhuber J, Herrmann M, Wiltfang J.
Distinct fractional Abeta release patterns in human mononuclear phagocytes. J Neuroimmunol. 2009;206(1-2): 1-4

2008

Mamo JC, Jian L, James AP, Flicker L, Esselmann H, Wiltfang J
Plasma lipoprotein beta-amyloid in subjects with Alzheimer's disease or mild cognitive impairment.
Ann Clin Biochem. 2008;45(Pt 4): 395-403

Henkel AW, Sperling W, Rotter A, Reulbach U, Reichardt C, Bönsch D, Maler JM, Kornhuber J, Wiltfang J
Antidepressant drugs modulate growth factors in cultured cells.
BMC Pharmacol. 2008;8: 6

Maler JM, Spitzer P, Klafki HW, Esselmann H, Bibl M, Lewczuk P, Kornhuber J, Herrmann M, Wiltfang J
Adherence-dependent shifts in the patterns of beta-amyloid peptides secreted by human mononuclear phagocytes.
Brain Behav Immun. 2008;22(7): 1044-8

Bibl M, Mollenhauer B, Esselmann H, Schneider M, Lewczuk P, Welge V, Gross M, Falkai P, Kornhuber J, Wiltfang J
Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review.
Dement Geriatr Cogn Disord. 2008;25(3): 256-65

Wittchen HU, Apelt SM, Soyka M, Gastpar M, Backmund M, Gölz J, Kraus MR, Tretter F, Schäfer M, Siegert J, Scherbaum N, Rehm J, Bühringer G
Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients.
Drug Alcohol Depend. 2008;95(3): 245-57

Lewczuk P, Hornegger J, Zimmermann R, Otto M, Wiltfang J, Kornhuber J
Neurochemical dementia diagnostics: assays in CSF and blood.
Eur Arch Psychiatry Clin Neurosci. 2008;258 Suppl : 44-9

Reissner V, Baune B, Votsidi V, Schifano F, Room R, Stohler R, Schwarzer C, Scherbaum N
Burnout, coping and job satisfaction in service staff treating opioid addicts - from Athens to Zurich
Eur Psychiatry. 2008;23: S88-S88

Reissner V, Kokkevi A, DiFuria L, Schiffano E, Room R, Stohler R, Scherbaum N
Drug consumption, health service use and outcome in opiate addicts in Europe: An 18-month follow-up from athens to zurich
Eur Psychiatry. 2008;23: S74-S75

Bibl M, Wiltfang J
Diagnostic and prognostic needs in neurodegenerative disorders: focus on proteomics.
Expert Rev Proteomics. 2008;5(2): 153-6

Diehl A, Scherbaum N
[Nicotine dependence as comorbidity of alcohol dependence - epidemiology, etiology and therapy.]
Fortschr Neurol Psychiatr. 2008;76(1): 14-8

Lieb B, Rosien M, Bonnet U, Scherbaum N
[Unhealthy alcohol use in the elderly--current screening and treatment strate-gies]
Fortschr Neurol Psychiatr. 2008;76(2): 75-85

Scherbaum N, Specka M
Factors influencing the course of opiate addiction.
Int J Methods Psychiatr Res. 2008;17(1 Suppl): S39-44

Czirr E, Cottrell BA, Leuchtenberger S, Kukar T, Ladd TB, Esselmann H, Paul S, Schubenel R, Torpey JW, Pietrzik CU, Golde TE, Wiltfang J, Baumann K, Koo EH, Weggen S
Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase.
J Biol Chem. 2008;283(25): 17049-54

Nyhuis PW, Gastpar M, Scherbaum N
Opiate treatment in depression refractory to antidepressants and electrocon-vulsive therapy.
J Clin Psychopharmacol. 2008;28(5): 593-5

Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, Gann H, Mann KF, ACTOL Study Investigators
Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of al-cohol dependence: results from a placebo-controlled, double-blind trial.
J Clin Psychopharmacol. 2008;28(3): 317-24

Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
J Med Chem. 2008;51(2): 219-37

Kessler H, Pajonk FG, Bach D, Schneider-Axmann T, Falkai P, Herrmann W, Multhaup G, Wiltfang J, Schäfer S, Wirths O, Bayer TA
Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial.
J Neural Transm. 2008;115(12): 1651-9

Meuth SG, Simon OJ, Grimm A, Melzer N, Herrmann AM, Spitzer P, Landgraf P, Wiendl H
CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing.
J Neuroimmunol. 2008;194(1-2): 62-9

Kis B, Rumberg B, Berlit P
Clinical characteristics of patients with late-onset multiple sclerosis.
J Neurol. 2008;255(5): 697-702

Alvarez I, de la Torre A, Sainz M, Roldan C, Schoesser H, Spitzer P
An improved masker-probe method for stimulus artifact reduction in electrically evoked compound action potentials.
J Neurosci Methods. 2008;175(1): 143-7

Bonnet U, Harkener J, Scherbaum N
A case report of propofol dependence in a physician.
J Psychoactive Drugs. 2008;40(2): 215-7

Salloum S, Oniangue-Ndza C, Neumann-Haefelin C, Hudson L, Giugliano S, aus dem Siepen M, Nattermann J, Spengler U, Lauer GM, Wiese M, Klener-man P, Bright H, Scherbaum N, Thimme R, Roggendorf M, Viazov S, Timm J
Escape from HLA-B*08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs.
J Virol. 2008;82(23): 11803-12

Otto M, Lewczuk P, Wiltfang J
Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases.
Methods. 2008;44(4): 289-98

Hölscher F, Bonnet U, Scherbaum N
[Use of an outpatient treatment center for cannabis abuse]
Nervenarzt. 2008;79(5): 571-6

Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönk-necht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J
Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
Neurobiol Aging. 2008;29(6): 812-8

Kölsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Kornhuber J, Frölich L, Heuser I, Peters O, Schulz JB, Schwab SG, Maier W
Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease.
Neurosci Lett. 2008;440(1): 68-71

Bonnet U, Scherbaum N, Wiemann M
The endogenous alkaloid harmane: Acidifying and activity-reducing effects on hippocampal neurons in vitro.
Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2): 362-7

Svitek J, Heberlein A, Bleich S, Wiltfang J, Kornhuber J, Hillemacher T Extensive craving in high dose zolpidem dependency.
Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2): 591-2

Bibl M, Lewczuk P, Esselmann H, Mollenhauer B, Klafki HW, Welge V, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J
CSF amyloid-beta 1-38 and 1-42 in FTD and AD: Biomarker performance criti-cally depends on the detergent accessible fraction
PROTEOMICS CLINICAL APPLICATIONS. 2008;2(10-11): 1548-1556

Brechlin P, Jahn O, Steinacker P, Cepek L, Kratzin H, Lehnert S, Jesse S, Mollenhauer B, Kretzschmar HA, Wiltfang J, Otto M
Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease.
Proteomics. 2008;8(20): 4357-66

Hamacher M, Eisenacher M, Tribl F, Stephan C, Marcus K, Hardt T, Wiltfang J, Martens L, Desiderio D, Gutstein H, Park YM, Meyer HE
The HUPO Brain Proteome project wish list--summary of the 9(th) HUPO BPP Workshop 9-10 January 2008, Barbados.
Proteomics. 2008;8(11): 2160-4

Hamacher M, Stephan C, Hardt T, Eisenacher M, Henkel A, Wiltfang J, Jime-nez CR, Park YM, Marcus K, Meyer HE
Applications in brain proteomics: 8(th) HUPO Brain Proteome Project Work-shop 7 October 2007, Seoul, Korea.
Proteomics. 2008;8(9): 1750-3

Lewczuk P, Wiltfang J
Neurochemical dementia diagnostics: State of the art and research perspectives.
Proteomics. 2008;8(6): 1292-301

Davids E, Schieder M, Specka M, Wessels T, Scherbaum N
Pharmacological treatment in schizophrenic patients with severe relapses - development between 1993 and 2004
Psychopharmakotherapie. 2008;15(3): 122-125

2007

Weber W, Kis B, Siekmann R, Kuehne D
Endovascular treatment of intracranial arteriovenous malformations with onyx: technical aspects.
AJNR Am J Neuroradiol. 2007;28(2): 371-7

Scherbaum N, Bonnet U, Schifano F, Birkemeyer W, Hufnagel A, Schmitz D, Sipal SC, Wiemer P, Wurthmann C
Low Hospital Admission Rates Following MDMA (Ecstasy) Intake in Essen (Germany).
Am J Addict. 2007;16(5): 428-9

Auditory target processing in methadone substituted opiate addicts: the effect of nicotine in controls.
BMC Psychiatry. 2007;7: 63

Kuhlenbaumer G, Friedrichs F, Kis B, Berlit P, Maintz D, Nassenstein I, Nabavi D, Dittrich R, Stoll M, Ringelstein B 
Association between Single Nucleotide Polymorphisms in the Lysyl Oxidase-Like 1 Gene and Spontaneous Cervical Artery Dissection.
Cerebrovasc Dis. 2007;24(4): 343-8

Jäger M, Riedel M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gae-bel W, Huff W, Heuser I, Kühn KU, Lemke MR, Rüther E, Buchkremer G, Gastpar M, Bottlender R, Strauß A, Möller HJ
Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders.
Eur Arch Psychiatry Clin Neurosci. 2007;257(1): 47-53

Müller BW, Gimbel K, Keller-Pliessnig A, Sartory G, Gastpar M, Davids E 
Neuropsychological assessment of adult patients with attentiondeficit/hyperactivity disorder.
Eur Arch Psychiatry Clin Neurosci. 2007;257(2): 112-9

Trippler M, Wang B, Erim Y, Bein S, Scherbaum N, Gerken G, Schlaak JF
Common pathways in endogenous depression and in IFN-induced depression in HCV patients
Hepatology. 2007;46 Suppl.(4): 850A-850A

Bender S, Scherbaum N, Soyka M, Rüther E, Mann K, Gastpar M
The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining absti-nence: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients.
Int J Neuropsychopharmacol. 2007;: 1-8

Kis B, Seo BK, Sartory G, Davids E, Scherbaum N, Muller BW
The intensity dependent amplitude increase of the auditory evoked potential in adults with persistent attention-deficit/hyperactivity disorder
J Neural Transm. 2007;114(7): LXXVIII-LXXVIII

Kis B, Tagay S, Muller BW, Davids E, Scherbaum N
Quality of life of adults with attention-deficit/hyperactivity disorder: a system-atic study
J Neural Transm. 2007;114(7): LXV-LXVI

Muller B, Seo BK, Kis B, Sartory G, Davids E, Scherbaum N
The auditory oddball paradigm in adults with persistent attention-deficit/hyperactivity disorder
J Neural Transm. 2007;114(7): LXXVIII-LXXIX

Seo BK, Kis B, Sartory G, Davids E, Scherbaum N, Muller B
The readiness potential in adults with persistent attention deficit/hyperactivity disorder
J Neural Transm. 2007;114(7): LXXIX-LXXIX

Albayrak O, Krug S, Scherbaum N
[Sex-specific aspects of addiction]
MMW Fortschr Med. 2007;149(24): 29-32

Scherbaum N
[Maintenance treatment of opiate addicts.]
Nervenarzt. 2007;78(1): 103-110

Weber W, Bendszus M, Kis B, Boulanger T, Solymosi L, Kühne D
A new self-expanding nitinol stent (Enterprise) for the treatment of wide-necked intracranial aneurysms: initial clinical and angiographic results in 31 aneurysms.
Neuroradiology. 2007;49(7): 555-61

Weber W, Kis B, Siekmann R, Jans P, Laumer R, Kühne D
Preoperative embolization of intracranial arteriovenous malformations with Onyx.
Neurosurgery. 2007;61(2): 244-52; discussion 252-4

Bonnet U, Specka M, Leweke FM, Nyhuis P, Banger M
Gabapentin's acute effect on mood profile -- a controlled study on patients with alcohol withdrawal.
Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2): 434-8

Wessels T, Grünler D, Bunk C, Specka M, Gastpar M, Scherbaum N, Davids E
Changes in the treatment of acute psychosis in a German public hospital from 1998 to 2004.
Psychiatr Q. 2007;78(2): 91-9

Davids E, Bunk C, Scherbaum N, Wessels T
Retrospective analysis of psychotropic drug prescription in patients with Alzheimer's disease
Psychopharmakotherapie. 2007;14(6): 253-256

2006

Chen L, Kis B, Hashimoto H, Busija DW, Takei Y, Yamashita H, Ueta Y
Adrenomedullin 2 protects rat cerebral endothelial cells from oxidative damage in vitro.
Brain Res. 2006;1086(1): 42-9

Ayzenberg I, Obermann M, Nyhuis P, Gastpar M, Limmroth V, Diener HC, Kaube H, Katsarava Z
Central sensitization of the trigeminal and somatic nociceptive systems in me-dication overuse headache mainly involves cerebral supraspinal structures.
Cephalalgia. 2006;26(9): 1106-14

Juptner M
NIMH-study on the effectiveness of antipsychotic drugs in Alzheimer's demen-tia
Dtsch Z Nervenheilkd. 2006;25(6): 492-493

Gruenler D, Bunk C, Specka M, Gastpar M, Davids E
Pattern of neuroleptic drug use in acute schizophrenia
Eur Neuropsychopharmacol. 2006;16 Suppl.: S411-S411

Linka T, Sartory G, Muller BW
Clinical symptoms of major depression are associated with the intensity de-pendence of auditory evoked ERP components
Eur Neuropsychopharmacol. 2006;16 Suppl.: S313-S313

Nyhuis PW, Specka M, Gastpar M
Does the antidepressive response to opiate treatment describe a subtype of depression?
Eur Neuropsychopharmacol. 2006;16 Suppl.: S309-S309

Wittchen HU, Apelt SM, Soyka M, Gastpar M, Backmund M, Goelz J, Kraus M, Tretter F, Schaefer M, Siegert J, Guenther A, Rehm J, Buehringer G
One year retention rates and outcomes of methadone and buprenorphine maintenance treatments: a nationwide prospectivelongitudinal study of 2694 patients
Eur Neuropsychopharmacol. 2006;16 Suppl.: S504-S505

Zumdick S, Schneider U, Leweke M, Jülicher A, Tossmann P, Bonnet U
[A survey on trials focussing on the treatment of cannabis-dependence]
Fortschr Neurol Psychiatr. 2006;74(4): 211-25

Siemann H, Specka M, Schifano F, Deluca P, Scherbaum N
[Salvia divinorum--representation of a new drug in the Internet]
Gesundheitswesen. 2006;68(5): 323-7

Heinze S, Sartory G, Muller BW, de Greiff A, Forsting M, Juptner M
Neural encoding correlates of high and low verbal memory performance
J Psychophysiol. 2006;20(2): 68-78

Nyhuis PW
[Maintenance treatment and relapse prophylaxis of depressive disorders]
MMW Fortschr Med. 2006;148(4): 26-8, 30

Kis B, Weber W, Berlit P, Kühne D
Elective treatment of saccular and broad-necked intracranial aneurysms using a closed-cell nitinol stent (Leo).
Neurosurgery. 2006;58(3): 443-50; discussion 443-50

Gastpar M, Singer A, Zeller K
Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study.
Pharmacopsychiatry. 2006;39(2): 66-75

Bonnet U, Davids E
A rare case of dependence on pemoline.
Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(7): 1340-1

Davids E, Kis B, Specka M, Gastpar M
A pilot clinical trial of oxcarbazepine in adults with attention-deficit hyperactiv-ity disorder.
Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6): 1033-8

Davids E, Bunk C, Specka M, Gastpar M
Psychotropic drug prescription in a psychiatric university hospital in Germany.
Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6): 1109-16

Schifano F, Deluca P, Baldacchino A, Peltoniemi T, Scherbaum N, Torrens M, Farre M, Flores I, Rossi M, Eastwood D, Guionnet C, Rawaf S, Agosti L, Di Furia L, Brigada R, Majava A, Siemann H, Leoni M, Tomasin A, Rovetto F, Ghodse AH 
Drugs on the web; the Psychonaut 2002 EU project.
Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4): 640-6

Heinze S, Sartory G, Müller BW, de Greiff A, Forsting M, Jüptner M
Neural activation during successful and unsuccessful verbal learning in schi-zophrenia.
Schizophr Res. 2006;83(2-3): 121-30

Kircher T, Thienel R, Habel U, Klein M, Kellermann T, Braus DF, Schmitt A, Wagner M, Frommann I, Schlosser R, Ruhrmann S, Muller BW, Gaebel W, Maier W, Schneider F 
Variation in NRG 1 affects cerebral activation during a working memory task in first episode schizophrenia
Schizophr Res. 2006;81 Suppl.: 191-192

2005

Scherbaum N, Baune BT, Mikolajczyk R, Kuhlmann T, Reymann G, Reker M
Prevalence and risk factors of syphilis infection among drug addicts.
BMC Infect Dis. 2005;5(1): 33

Splettstoesser F, Bonnet U, Wiemann M, Bingmann D, Büsselberg D
Modulation of voltage-gated channel currents by harmaline and harmane.
Br J Pharmacol. 2005;144(1): 52-8

Scherbaum N, Kluwig J, Meiering C, Gastpar M
Use of illegally acquired medical opioids by opiate-dependent patients in de-toxification treatment.
Eur Addict Res. 2005;11(4): 193-6

Scherbaum N, Kluwig J, Specka M, Krause D, Merget B, Finkbeiner T, Gastpar M
Group psychotherapy for opiate addicts in methadone maintenance treatment--a controlled trial.
Eur Addict Res. 2005;11(4): 163-71

Kis B, Specka M, Gastpar M, Davids E
Oxcarbazepine in adults with attention deficit hyperactivity disorder: a clinical pilot trial
Eur Neuropsychopharmacol. 2005;15 Suppl.: S595-S595

Nyhuis P, Gastpar M 
Opiate treatment in ECT-resistant depression
Eur Neuropsychopharmacol. 2005;15 Suppl.: S420-S420

Scherbaum N
Evaluation of drug consumption rooms for drug addicts
Eur Psychiatry. 2005;20 Suppl.: S15-S15

Chrzanowski W, Latif M, Masiak M, Medori R, Gastpar M
Olanzapine-treated patients with psychotic disorders improved after changing to risperidone long-acting injectable
Eur Psychiatry. 2005;20 Suppl.: S66-S66

Gastpar M, Vetterli M
Power, spatio-temporal bandwidth, and distortion in large sensor networks
IEEE J Sel Areas Commun. 2005;23(4): 745-754

Wittchen HU, Apelt SM, Bühringer G, Gastpar M, Backmund M, Gölz J, Kraus MR, Tretter F, Klotsche J, Siegert J, Pittrow D, Soyka M
Buprenorphine and methadone in the treatment of opioid dependence: meth-ods and design of the COBRA study.
Int J Methods Psychiatr Res. 2005;14(1): 14-28

Kis B, Weber W, Nickel S, Jans P, Latimer R, Berlit P, Kuhne D
Endovascular therapy of occipital arteriovenous malformations using ONYX (TM)
J Neurol. 2005;252 Suppl.: 8-8

Maschke M, Weber J, Bonnet U, Dimitrova A, Bohrenkämper J, Sturm S, Mül-ler BW, Gastpar M, Diener HC, Forsting M, Timmann D
Vermal atrophy of alcoholics correlate with serum thiamine levels but not with dentate iron concentrations as estimated by MRI.
J Neurol. 2005;252(6): 704-11

Gastpar M, Masiak M, Latif MA, Frazzingaro S, Medori R, Lombertie ER
Sustained improvement of clinical outcome with risperidone long-acting in-jectable in psychotic patients previously treated with olanzapine.
J Psychopharmacol. 2005;19(5 Suppl): 32-8

Schifano F, Deluca P, Agosti L, Martinotti G, Corkery JM, Alex B, Caterina B, Heikki B, Raffaella B, Anna C, Lucia DF, Dorte DR, Magi F, Susana F, Irene F, Claude G, Lisbet H, Lene SJ, Mauro L, Christopher L, Aino M, Teuvo P, Mile-na P, Salman R, Damien R, Angela RM, Francesco R, Norbert S, Holger S, Josep T, Marta T, Francesco Z, Psychonaut 2002 Research Group
New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic').
J Psychopharmacol. 2005;19(6): 675-9

Kis B, Hedrich K, Kann M, Schwinger E, Kompf D, Klein C, Pramstaller PP
Oculogyric dystonic states in early-onset parkinsonism with basal ganglia calcifications
Neurology. 2005;65(5): 761-761

Davids E, Specka M, Gastpar M
A pilot clinical trial of oxcarbazepine in adults with attention deficit hyperactivity disorder
Pharmacopsychiatry. 2005;38(5): 235-236

Gastpar M, Singer A, Zeller K
Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline.
Pharmacopsychiatry. 2005;38(2): 78-86

Linka T, Müller BW, Bender S, Sartory G, Gastpar M
The intensity dependence of auditory evoked ERP components predicts re-sponsiveness to reboxetine treatment in major depression.
Pharmacopsychiatry. 2005;38(3): 139-43

Nyhuis PW, Gastpar M
Opiate treatment in ECT-resistant depression
Pharmacopsychiatry. 2005;38(5): 267-267

Schürks M, Overlack M, Bonnet U
Naltrexone treatment of combined alcohol and opioid dependence: deteriora-tion of co-morbid major depression.
Pharmacopsychiatry. 2005;38(2): 100-2

Davids E, von Bünau U, Specka M, Fischer B, Scherbaum N, Gastpar M
History of attention-deficit hyperactivity disorder symptoms and opioid de-pendence: a controlled study.
Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(2): 291-6

Davids E, Gastpar M
Attention deficit hyperactivity disorder and borderline personality disorder.
Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6): 865-77

Gastpar M
Significance of tricyclic Antidepressiva in modern antidepressive therapy
Psychopharmakotherapie. 2005;12(4): 24-25

Gastpar M, Zeller K
Comparison of hypericum extract STW3 and sertraline in the treatment of moderate depression: a double-blind randomized 24-week-study
Psychopharmakotherapie. 2005;12(4): 146-153

Kasper S, Gastpar M, Muller WE
Effectiveness of anti-depressives: Differentiated evaluation instead of global review is questioned
Psychopharmakotherapie. 2005;12(5): 193-194

Moller HJ, Laux G, Naber D, Gastpar MT, Klosterkotter J, Schmauss M, Heeg B, Van Gestel A, Van Hout B, Mehnert A
Costs and effects of long-acting risperidone in comparison to oral atypical and conventional depot formulations for the treatment of patients with schizophre-nia in Germany
Psychopharmakotherapie. 2005;12(5): 183-192

Medori R, Vidal DJP, Bleuer S, Gastpar M
Improved symptom control and functioning in patients with psychotic disorders following treatment change from olanzapine to risperidone long-acting in-jectable
Schizophr Bull. 2005;31(2): 497-497  

2004

2003

Kienbaum P, Peters J, Scherbaum N
Convincing effects of clonidine on neurohumoral withdrawal symptoms during antagonist-supported detoxification of opioid addicts.
Anesth Analg. 2003;97(5): 1547-8; author reply 1547

Davids E, Zhang K, Tarazi FI, Baldessarini RJ
Animal models of attention-deficit hyperactivity disorder.
Brain Res Brain Res Rev. 2003;42(1): 1-21

Bonnet U
Moclobemide: therapeutic use and clinical studies.
CNS Drug Rev. 2003;9(1): 97-140

Kavuk I, Agelink MW, Gaertner T, Kastrup O, Doerfler A, Maschke M, Diener HC
Wernicke's encephalopathy: unusual contrast enhancement revealed by mag-netic resonance imaging.
Eur J Med Res. 2003;8(11): 492-4

Davids E, Rösinger C, Reinhold U, Gastpar M
[Life events and contact behaviour in drug-related death]
Fortschr Neurol Psychiatr. 2003;71(3): 135-40

Bonnet U, Banger M, Leweke FM, Specka M, Müller BW, Hashemi T, Nyhuis PW, Kutscher S, Burtscheidt W, Gastpar M
Treatment of acute alcohol withdrawal with gabapentin: results from a con-trolled two-center trial.
J Clin Psychopharmacol. 2003;23(5): 514-9

Tarazi FI, Zhang K, Davids E, Baldessarini RJ
Dopamine D-4 receptors and ADHD: new genetic linkage, novel pharmaco-therapeutic target
J Neurochem. 2003;87 Suppl.: 66-66

Thümler BH, Urban PP, Davids E, Siessmeier M, Schreckenberger T, Benz P, Stoeter P, Bartenstein P, Hopf HC
Dysarthria and pathological laughter/crying as presenting symptoms of corti-cobasal-ganglionic degeneration syndrome.
J Neurol. 2003;250(9): 1107-8

Moeller P, Hetzel G, Rothermundt M, Michael N, Nyhuis PW, Suslow T, Arolt V, Erfurth A
Oral citalopram and reboxetine challenge tests before and after selective anti-depressant treatment.
J Psychiatr Res. 2003;37(3): 261-2

Gerlach AL, Schon S, Scherbaum N, Rist F
Physiological reactions and craving induced by drug-associated videos
J Psychophysiol. 2003;17(3): 149-149

Heinze S, Sartory G, Mueller BW, de Greiff A, Forsting M, Juptner M
Short versus long term verbal memory: A comparison of encoding patterns
J Psychophysiol. 2003;17(3): 153-153

Muller BW, Stude P, Nebel K, Wiese H, Ladd M, Forsting M, Juptner M
Sparse imaging of the P300 equivalent with functional MRI
J Psychophysiol. 2003;17(3): 168-169

Scherbaum N, Kienbaum P
[Ultrashort withdrawal from opiate dependence]
Med Monatsschr Pharm. 2003;26(8): 278-82

Schall U, Johnston P, Lagopoulos J, Jüptner M, Jentzen W, Thienel R, Ditt-mann-Balçar A, Bender S, Ward PB
Functional brain maps of Tower of London performance: a positron emission tomography and functional magnetic resonance imaging study.
Neuroimage. 2003;20(2): 1154-61

Grunder G, Vernaleken I, Muller MJ, Davids E, Heydari N, Buchholz HG, Bartenstein P, Munk OL, Stoeter P, Wong DF, Gjedde A, Cumming P
Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo
Neuropsychopharmacology. 2003;28(4): 787-794

Müller BW, Stude P, Nebel K, Wiese H, Ladd ME, Forsting M, Jueptner M
Sparse imaging of the auditory oddball task with functional MRI.
Neuroreport. 2003;14(12): 1597-601

Bender S, Linka T, Grohmann R, Engel RR, Degner D, Ruther E
Severe adverse drug reactions of typical and atypical neuroleptics in routine clinical treatment: results from the AMSP drug safety program Pharmacopsychiatry. 2003;36(5): 214-214

Bender S, Olbrich HM, Fischer W, Hornstein C, Schoene W, Falkai P, Haar-mann C, Berger M, Gastpar M
Antipsychotic efficacy of the antidepressant trimipramine: a randomized, dou-ble-blind comparison with the phenothiazine perazine.
Pharmacopsychiatry. 2003;36(2): 61-9

Linka T, Muller BW, Hesse A, Bender S, Sartory G
The intensity dependence of the auditory evoked N1/P2-ERP-component in-creases in pharmacotherapy of major depression with citalopram
Pharmacopsychiatry. 2003;36(5): 244-245

Nyhuis PW, Ekrod K, Gastpar M
Gabapentin as a mood stabiliser in the treatment of alcoholism-SAD-comorbidity
Pharmacopsychiatry. 2003;36(5): 252-252

Scherbaum N, Heppekausen K, Rist F
Is premature termination of opiate detoxification due to intensive withdrawal or craving?
Pharmacopsychiatry. 2003;36(5): 259-259

Scherbaum N, Stüper B, Bonnet U, Gastpar M
Transient restless legs-like syndrome as a complication of opiate withrawal.
Pharmacopsychiatry. 2003;36(2): 70-2

Schmidt LG, Degner D, Grohmann R, Kropp S, Bender S, Engel RR, Ruther E
Severe adverse drug reactions of antidepressants: Results of the German Multicenter Drug Surveillance Program AMSP
Pharmacopsychiatry. 2003;36(5): 261-261

Gastpar M, Klimm HD
Treatment of anxiety, tension and restlessness states with Kava special ex-tract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial.
Phytomedicine. 2003;10(8): 631-9

Davids E, Gastpar M
[Attention-deficit/hyperactivity disorder and substance abuse]
Psychiatr Prax. 2003;30(4): 182-6

Davids E, Reinhold U, Rösinger C, Gastpar M
[Descriptive analysis of drug-related deaths over a 5-year period]
Psychiatr Prax. 2003;30(5): 266-71

Laux G, Gastpar M, Depression A
Acute treatment of depression by primary physician
Psychopharmakotherapie. 2003;10(1): 3-4

Strebel B, Kuhnigk O, Juptner M, Schilauske J
Attitudes of medical students toward psychotherapy as a function of the aca-demic semester - Gender and prior experience with psychiatry and psychotherapy
Psychother Psychosom Med Psychol. 2003;53(2): 140-141

Teusch L, Bohme H, Finke J, Gastpar M, Skerra B
Antidepressant medication and the assimilation of problematic experiences in psychotherapy
Psychotherapie Research. 2003;13(3): 307-322

Bender S, Thienel R, Dittmann-Balcar A, Tackenberg A, Gastpar M
Training effects of computer-based cognitive training in patients with schizo-phrenia
Schizophr Res. 2003;60 Suppl.(1): 124-124

Linka T, Dittmann-Balcar A, Grohmann R, Bender S
Assessment of sexual dysfunctions in schizophrenic inpatients with the AMSP drug safety program
Schizophr Res. 2003;60 Suppl.(1): 361-362

Muller BW, Stude P, Ladd M, Nebel K, Wiese H, Forsting M, Juptner M
An assessment of the auditory P300 equivalent with sparse fMRI imaging
Schizophr Res. 2003;60 Suppl.(1): 229-229

Rasser PE, Johnston P, Lagopoulos J, Ward PB, Schall U, Thienel R, Bender S, Thompson PM
Analysis of fMRI bold activation during the Tower of London task using cortical pattern matching
Schizophr Res. 2003;60 Suppl.(1): 232-232

Thienel R, Bender S, Muller BW, Gizewski E, Schall U
Cognitive sub-components in solving the Tower of London test - An fMRI stu-dy in healthy volunteers and patients with schizophrenia
Schizophr Res. 2003;60 Suppl.(1): 235-235

2002

Scherbaum N, Gastpar M, Kuhlmann T, Reker M, Reymann G
Syphilis infection among drug addicts in western Germany.
Addiction. 2002;97(5): 601-2

Kienbaum P, Heuter T, Michel MC, Scherbaum N, Gastpar M, Peters J
Sympathetic neural activation evoked by mu-receptor blockade in patients ad-dicted to opioids is abolished by intravenous clonidine.
Anesthesiology. 2002;96(2): 346-51

Zhang K, Davids E, Tarazi FI, Baldessarini RJ
Serotonin transporter binding increases in caudate-putamen and nucleus ac-cumbens after neonatal 6-hydroxydopamine lesions in rats: implications for motor hyperactivity.
Brain Res Dev Brain Res. 2002;137(2): 135-8

Müller BW, Sartory G, Tackenberg A
The movement-related potential in children with migraine and tension-type headache.
Cephalalgia. 2002;22(2): 125-31

Bonnet U
Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.
CNS Drug Rev. 2002;8(3): 283-308

Leniger T, Wiemann M, Bingmann D, Widman G, Hufnagel A, Bonnet U
Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epilepti-form activity of hippocampal CA3 neurons.
Epilepsia. 2002;43(5): 469-74

Bonnet U, Bingmann D, Leniger T, Scherbaum N, Widman G, Hufnagel A, Wiemann M
Valproate acidifies hippocampal CA3-neurons--a novel mode of action.
Eur Neuropsychopharmacol. 2002;12(4): 279-85

Angst J, Gamma A, Gastpar M, Lépine JP, Mendlewicz J, Tylee A, Depression Research in European Society Study
Gender differences in depression. Epidemiological findings from the European DEPRES I and II studies.
Eur Arch Psychiatry Clin Neurosci. 2002;252(5): 201-9

Davids E, Hevers W, Dämgen K, Zhang K, Tarazi FI, Lüddens H
Organotypic rat cerebellar slice culture as a model to analyze the molecular pharmacology of GABAA receptors.
Eur Neuropsychopharmacol. 2002;12(3): 201-8

Tarazi FI, Zhang K, Davids E, Baldessarini RJ
Dopamine D-4 receptors mediate behavioral hyperactivity in juvenile rats
Eur Neuropsychopharmacol. 2002;12 Suppl.: S370-S371

Scherbaum N, Specka M, Hauptmann G, Gastpar M
[Does maintenance treatment reduce the mortality rate of opioid addicts?]
Fortschr Neurol Psychiatr. 2002;70(9): 455-61

Kienbaum P, Heuter T, Scherbaum N, Gastpar M, Peters J
Chronic mu-opioid receptor stimulation alters cardiovascular regulation in hu-mans: differential effects on muscle sympathetic and heart rate responses to arterial hypotension.
J Cardiovasc Pharmacol. 2002;40(3): 363-9

Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, Mendlewicz J, Möller HJ, Nemer-off CB, Saiz J, Such P, Torta R, Versiani M 
Partial response and nonresponse to antidepressant therapy: current ap-proaches and treatment options.
J Clin Psychiatry. 2002;63(9): 826-37

Gastpar M, Bonnet U, Böning J, Mann K, Schmidt LG, Soyka M, Wetterling T, Kielstein V, Labriola D, Croop R
Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study.
J Clin Psychopharmacol. 2002;22(6): 592-8

Davids E, Zhang K, Kula NS, Tarazi FI, Baldessarini RJ
Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats.
J Pharmacol Exp Ther. 2002;301(3): 1097-102

Sartory G, Heine A, Muller BW, Elvermann-Hallner A
Event- and motor-related potentials during the continuous performance task in attention-deficit/hyperactivity disorder
J Psychophysiol. 2002;16(2): 97-106

Banger M
Affective syndrome during perimenopause.
Maturitas. 2002;41 Suppl 1: S13-8

PLUM FJ, LODEMANN E, BENDER S, FINKBEINER T, GASTPAR M
CHANGES OF CONTACT BEHAVIOUR, MUSICAL EXPRESSION, AND PSYCHOPATHOLOGICAL STATE OF SCHIZOPHRENIC PATIENTS DUR-ING MUSIC THERAPY IN GROUP
NERVENHEILKUNDE. 2002;21(10): 522-528

Grunze H, Walden J, Dittmann S, Berger M, Bergmann A, Bräunig P, Dose M, Emrich HM, Gastpar M, Greil W, Krüger S, Möller HJ, Uebelhack R
[Psychopharmacotherapy of bipolar affective diseases]
Nervenarzt. 2002;73(1): 4-17; quiz 18-9

Jüptner M, Paulus HJ, Gastpar M
[Delusional depression as differential dementia of the Alzheimer type diagno-sis]
Nervenarzt. 2002;73(5): 468-70

Müller BW, Jüptner M, Jentzen W, Müller SP
Cortical activation to auditory mismatch elicited by frequency deviant and complex novel sounds: a PET study.
Neuroimage. 2002;17(1): 231-9

Kutscher S, Heise DJ, Banger M, Saller B, Michel MC, Gastpar M, Schedlowski M, Exton M
Concomitant endocrine and immune alterations during alcohol intoxication and acute withdrawal in alcohol-dependent subjects.
Neuropsychobiology. 2002;45(3): 144-9

Zhang KH, Tarazi FI, Davids E, Baldessarini RJ
Plasticity of dopamine D-4 receptors in rat forebrain: Temporal association with motor hyperactivity following neonatal 6-hydroxydopamine lesioning
Neuropsychopharmacology. 2002;26(5): 625-633

Müller BW, Achenbach C, Oades RD, Bender S, Schall U
Modulation of mismatch negativity by stimulus deviance and modality of attention.
Neuroreport. 2002;13(10): 1317-20

Beck M, Mirmohammadsadegh A, Franz B, Blanke J, Hengge UR
Opioid receptors on white blood cells: effect of HIV infection and methadone treatment.
Pain. 2002;98(1-2): 187-94

Davids E, Müller MJ, Rollmann N, Burkart M, Regier-Klein E, Szegedi A, Benkert O, Maier W
Syndrome profiles in alcoholism and panic disorder with or without agoraphobia: an explorative family study.
Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(6): 1079-87

Davids E, Zhang KH, Tarazi FI, Baldessarini RJ
Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning
Psychopharmacology (Berl). 2002;160(1): 92-98

Zhang K, Davids E, Tarazi FI, Baldessarini RJ
Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions.
Psychopharmacology (Berl). 2002;161(1): 100-6

Naber D, Degner D, Bender S, Klimke A, Kuhn KU, Lambert M, Lemmer W, Riedel M, Vorbach EU, Dittmann RW
Olanzapine vs. clozapine: Findings on subjective well-being from a double-blind clinical trial
Schizophr Res. 2002;53 Sp. Iss(3): 176-176

Gastpar M, Reymann G
[Acute treatment of opiate addiction in patients in 2001]
Z Arztl Fortbild Qualitatssich. 2002;96(5): 301-6

2001

Allhoff T, Bender S, Banger M, Gastpar M, Sack S, Erbel R, Rehlinghaus U
Atrial arrhythmia in a woman treated with fluoxetine: is there a causal relationship?
Ann Emerg Med. 2001;37(1): 116-7

Kienbaum P, Heuter T, Michel MC, Scherbaum N, Gastpar M, Peters J
Chronic mu-opioid receptor stimulation in humans decreases muscle sympathetic nerve activity.
Circulation. 2001;103(6): 850-5

Scherbaum N
[The indication for heroin prescription - considerations with the historical ex-ample of the opiate addicted Swiss author Friedrich Glauser (1896 - 1938)]
Fortschr Neurol Psychiatr. 2001;69(10): 468-73

Ward PB, Schall U, Lagopoulos J, Bender S, Little C
Functional brain imaging of increasing task difficulty, in the Tower of London, in patients with schizophrenia and healthy volunteers
Int J Psychophysiol. 2001;41(3): 223-223

Allhoff T, Renzing-Köhler K, Dietrich U, Sack S, Banger M, Gastpar M
Somatic comorbidity of addicts: does hospitalization yield relevant findings?
J Addict Dis. 2001;20(2): 85-95

Agelink MW, Majewski T, Wurthmann C, Postert T, Linka T, Rotterdam S, Kli-eser E
Autonomic neurocardiac function in patients with major depression and effects of antidepressive treatment with nefazodone.
J Affect Disord. 2001;62(3): 187-98

Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T, Klieser E
Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine.
J Clin Psychopharmacol. 2001;21(1): 8-13

Grzella I, Müller BW, Oades RD, Bender S, Schall U, Zerbin D, Wolstein J, Sartory G
Novelty-elicited mismatch negativity in patients with schizophrenia on admis-sion and discharge.
J Psychiatry Neurosci. 2001;26(3): 235-46

Muller BW, Achenbach C, Oades RD, Schall U
Duration- but not novelty-elicited mismatch negativity increases with attention: A test/retest study
J Psychophysiol. 2001;15(2): 139-140

Muller BW, Grzella I, Oades RD, Bender S, Wolstein J, Schall U, Zerbin D, Sartory G
Novelty-elicited mismatch negativity (MMN) on admission and discharge in schizophrenia: MMN decreases with treatment
J Psychophysiol. 2001;15(2): 140-140

Oades RD, Schall U, Bender S, Wolstein J
Automatic and controlled attentional processes in schizophrenia: Topographic event-related potentials
J Psychophysiol. 2001;15(1): 56-56

Sartory G, Heine A, Muller BW, Elvermann A
Slow cortical potentials during the continuous performance test in attention de-ficit/hyperactivity disorder
J Psychophysiol. 2001;15(2): 147-147

Davalos DB, Merikangas J, Bender S
Psychosis in hypomelanosis of Ito.
J R Soc Med. 2001;94(3): 140-1

Scherbaum N, Beckmann JP, Klein S, Rehm J
[Medical ethics of heroin prescription by physicians]
Nervenarzt. 2001;72(9): 717-22

Teusch L, Böhme H, Finke J
[Conflict-centered individual therapy or integration of psychotherapy methods. Process of change in client-centered psychotherapy with and without behavioral exposure therapy in agoraphobia with panic disorder]
Nervenarzt. 2001;72(1): 31-9

Ward PB, Schall U, Lagopoulos J, Bender S, Little C
Functional brain imaging of increasing task difficulty in the Tower of London in patients with schizophrenia and healthy volunteers: An fMRI study
Neuroimage. 2001;13(6): S1114-S1114

Jueptner M, Krukenberg M
Motor system: cortex, basal ganglia, and cerebellum.
Neuroimaging Clin N Am. 2001;11(2): 203-19, viii

Evers S, Bockermann I, Nyhuis PW
The impact of transcranial magnetic stimulation on cognitive processing: an event-related potential study
Neuroreport. 2001;12(13): 2915-2918

Dittmann-Balçar A, Jüptner M, Jentzen W, Schall U
Dorsolateral prefrontal cortex activation during automatic auditory duration-mismatch processing in humans: a positron emission tomography study.
Neurosci Lett. 2001;308(2): 119-22

Teusch L, Böhme H, Finke J, Gastpar M
Effects of client-centered psychotherapy for personality disorders alone and in combination with psychopharmacological treatment. An empirical follow-up study.
Psychother Psychosom. 2001;70(6): 328-36

Bender S, Müller B, Oades RD, Sartory G
Conditioned blocking and schizophrenia: a replication and study of the role of symptoms, age, onset-age of psychosis and illness-duration.
Schizophr Res. 2001;49(1-2): 157-70

Bender S, Dittmann-Balcar A, Prehn G, Peters S, Gastpar M
How do patients with schizophrenia experience computer-assisted cognitive training?
Schizophr Res. 2001;49 Sp. Iss(1-2): 257-257

Dittmann-Balcar A, Juptner M, Muller S, Schall UA
Functional neuroimaging of automatic and active auditory discrimination proc-essing
Schizophr Res. 2001;49 Sp. Iss(1-2): 176-176

Mueller BW, Juptner M, Sartory G, Forsting M
Cerebellar activation during auditory information processing: An fMRI study assessing temporal discrimination with and without directed attention
Schizophr Res. 2001;49(1-2): 182-182

Naber D, Bandelow B, Bender S, Klimke A, Kuhn K, Lambert M, Lemmer W, Riedel M, Vorbach E, Dittmann RW
Subjective well-being under neuroleptic treatment with olanzapine versus clo-zapine: First results from a double-blind clinical trial using the SWN selfrating scale
Schizophr Res. 2001;49 Sp. Iss(1-2): 240-240

Thienel R, Bender S, Oades RD, Dittmann-Balcar A, Rao M, Schall UA
Auditory gating, neuropsychology and D2-receptor occupancy in an one-year follow-up treatment study on schizophrenia
Schizophr Res. 2001;49 Sp. Iss(1-2): 210-210

Ward PB, Schall UA, Juptner M, Muller S, Lagopoulos J, Bender S, Little CL
Functional neuroimaging of increasing task difficulty in the Tower of London: A comparison of bold fMRI and rCBF PET data
Schizophr Res. 2001;49 Sp. Iss(1-2): 188-189

2000

Wang GJ, Volkow ND, Franceschi D, Fowler JS, Thanos PK, Scherbaum N, Pappas N, Wong CT, Hitzemann RJ, Felder CA
Regional brain metabolism during alcohol intoxication.
Alcohol Clin Exp Res. 2000;24(6): 822-9

MIRZAIAN E, GASTPAR M
NEW ANTIDEPRESSANTS
AKTUEL NEUROL. 2000;27(3): 132-137

Oades RD, Rao ML, Bender S, Sartory G, Müller BW
Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy.
Behav Pharmacol. 2000;11(3-4): 317-30

Bonnet U, Leniger T, Wiemann M
Alteration of intracellular pH and activity of CA3-pyramidal cells in guinea pig hippocampal slices by inhibition of transmembrane acid extrusion.
Brain Res. 2000;872(1-2): 116-24

Leniger T, Wiemann M, Bingmann D, Hufnagel A, Bonnet U
Different effects of GABAergic anticonvulsants on 4-aminopyridine-induced spontaneous GABAergic hyperpolarizations of hippocampal pyramidal cells--implication for their potency in migraine therapy.
Cephalalgia. 2000;20(6): 533-7

Kienbaum P, Scherbaum N, Thürauf N, Michel MC, Gastpar M, Peters J
Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroen-docrine, metabolic, and cardiovascular patterns.
Crit Care Med. 2000;28(4): 969-76

Specka M, Finkbeiner T, Lodemann E, Leifert K, Kluwig J, Gastpar M
Cognitive-motor performance of methadone-maintained patients.
Eur Addict Res. 2000;6(1): 8-19

Bonnet U, Bingmann D, Wiemann M
Intracellular pH modulates spontaneous and epileptiform bioelectric activity of hippocampal CA3-neurones.
Eur Neuropsychopharmacol. 2000;10(2): 97-103

Muller BW, Achenbach C, Oades RD, Schall UC
Retest stability of attentional modulation in duration- and novelty-elicited mis-match negativity
Eur J Neurosci. 2000;12 Suppl.: 167-167

Muller BW, Achenbach C, Oades RD, Schall UC
Psychotherapy for opiate addicts in methadone substitution - A controlled trial
Eur Psychiatry. 2000;15 Suppl.: 237S-238S

Wolstein J, Grohmann R, Rüther E, Hippius H
Antipsychotic drugs and venous thromboembolism.
Lancet. 2000;356(9225): 252

Teusch L, Gastpar M
[Psychotherapy research in psychiatry. Results of a survey of psychiatric clinics]
Nervenarzt. 2000;71(3): 213-7

Bonnet U, Leniger T, Wiemann M
Moclobemide reduces intracellular pH and neuronal activity of CA3 neurones in guinea-pig hippocampal slices-implication for its neuroprotective properties.
Neuropharmacology. 2000;39(11): 2067-74

Muller BW, Juptner M, Muller S
Cortical activation associated with the processing of auditory frequency mis-match and complex novel sounds: A PET study
Psychophysiology. 2000;37 Suppl.: S73-S73

Teusch L, Finke J, Luderer HJ, Speierer GW
[Methodological openness as the basis of integrative psychotherapy]
Psychother Psychosom Med Psychol. 2000;50(1): 33-4

Muller BW, Sartory G, Bender S, Klimke A, Henning U
High dopamine impairs neuropsychological dysfunction in schizophrenia
Schizophr Res. 2000;41(1): 293-293

Oades RD, Muller BW, Bender S, Sartory G
A conditioned blocking impairment in nonparanoid schizophrenia: Onsetage and illness-duration
Schizophr Res. 2000;41(1): 292-293

Schall U, Bender S, Oades RD
'Prepulse-induced non-target positivity' (PINTP): A new ERP measure of selective attention deficits in schizophrenia
Schizophr Res. 2000;41(1): 149-149

Thienel R, Butorac M, Schall U, Bender S, Wolstein J, Dittmann-Balcar A, Oades RD
Tower of London performance in first to third episode patients with schizophrenia: A follow up study on executive function
Schizophr Res. 2000;41(1): 284-284

Ward PB, Schall U, Juptner M, Jentzen W, Muller S, Boden N, Lagopoulos J, Bender S, Little C
fMRI and pet activation during performance of the 'Tower of London' task
Schizophr Res. 2000;41(1): 132-132

Wolstein J, Bender S, Hesse A, Jura S, Dittmann-Balcar A
Leukocyte count increases with the addition of lithium to concurrent clozapine treatment
Schizophr Res. 2000;41(1): 185-185

Eap CB, Bender S, Gastpar M, Fischer W, Haarmann C, Powell K, Jonzier-Perey M, Cochard N, Baumann P
Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients.
Ther Drug Monit. 2000;22(2): 209-14

1999

ALLHOFF T, RENZING-KOHLER K, KIENBAUM P, SACK S, SCHERBAUM N
ELECTROCARDIOGRAPHIC ABNORMALITIES DURING RECOVERY FROM ULTRA-SHORT OPIATE DETOXIFICATION
Addict Biol. 1999;4(3): 337-344

Bonnet U, Wiemann M
Ammonium prepulse: effects on intracellular pH and bioelectric activity of CA3-neurones in guinea pig hippocampal slices.
Brain Res. 1999;840(1-2): 16-22

Allhoff T, Böhme-Molle J, Banger M
Combined alcohol dependence and personality disorder and its legal conse-quences with respect to commitment]
Fortschr Neurol Psychiatr. 1999;67(1): 1-6

Scherbaum N, Mirzaian E
Methodology of psychiatric case histories]
Fortschr Neurol Psychiatr. 1999;67(5): 229-36

VOLKAMER C
TREATING PARENTS - THE INDIVIDUAL PSYCHOTHERAPY AND AS-PECTS OF FAMILY DYNAMICS
NERVENHEILKUNDE. 1999;18(4): 218-220

Schepker R, Okur H
[Help in explaining to Turkish-speaking patients about the central affects of pharmaceuticals. Fact or fiction?]
Nervenarzt. 1999;70(5): 476-8

Dittmann-Balcar A, Thienel R, Schall U
Attention-dependent allocation of auditory processing resources as measured by mismatch negativity.
Neuroreport. 1999;10(18): 3749-53

Wiemann M, Schwark JR, Bonnet U, Jansen HW, Grinstein S, Baker RE, Lang HJ, Wirth K, Bingmann D
Selective inhibition of the Na+/H+ exchanger type 3 activates CO2/H+-sensitive medullary neurones.
Pflugers Arch. 1999;438(3): 255-62

BOHME H, TEUSCH L
THE INFLUENCE OF TEST DEFENSIVITY ON PSYCHOTHERAPY OUTCOME
PSYCHOTHERAPEUT. 1999;44(1): 36-43

FINKE J, TEUSCH L
OUTLINES OF A MANUAL-DIRECTED CLIENT-CENTERED THERAPY OF DEPRESSIVE DISORDERS
PSYCHOTHERAPEUT. 1999;44(2): 101-107

TEUSCH L, BOHME H
IS THE EXPOSURE PRINCIPLE REALLY CRUCIAL IN AGORAPHOBIA? THE INFLUENCE OF CLIENT-CENTERED NONPRESCRIPTIVE TREATMENT ON EXPOSURE
PSYCHOTHERAPY RESEARCH. 1999;9(1): 115-123

Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M
Treatment of alcohol withdrawal syndrome with gabapentin.
Pharmacopsychiatry. 1999;32(3): 107-9

Bender S, Schall U, Wolstein J, Grzella I, Zerbin D, Oades RD
A topographic event-related potential follow-up study on 'prepulse inhibition' in first and second episode patients with schizophrenia.
Psychiatry Res. 1999;90(1): 41-53

Kröner S, Schall U, Ward PB, Sticht G, Banger M, Haffner HT, Catts SV Effects of prepulses and d-amphetamine on performance and eventrelated potential measures on an auditory discrimination task.
Psychopharmacology (Berl). 1999;145(2): 123-32

WALDEN J, GRUNZE H, SCHLOSSER S, BERGER M, BERGMANN A, BRAUNIG P, DOSE M, EMRICH HM, GASTPAR M, GREIL W, MOLLER HJ, UBELHACK R
RECOMMENDATIONS FOR THE TREATMENT OF BIPOLAR AFFECTIVE DISORDER
Psychopharmakotherapie. 1999;6(3): 115-123

1998

Bender S, Eap CB
Very high cytochrome P4501A2 activity and nonresponse to clozapine.
Arch Gen Psychiatry. 1998;55(11): 1048-50